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Abstract
Epilysin (MMP-28) is the most recently identified member of the matrix metalloproteinase
(MMP) family of extracellular proteases. Together these enzymes are capable of degrading
almost all components of the extracellular matrix (ECM) and are thus involved in important
biological processes such as development, wound healing and immune functions, but also in
pathological processes such as tumor invasion, metastasis and arthritis. MMPs do not act
solely by degrading the ECM. They also regulate cell behavior by releasing growth factors
and biologically active peptides from the ECM, by modulating cell surface receptors and
adhesion molecules and by regulating the activity of many important mediators in
inflammatory pathways. The aim of this study was to define the unique role of epilysin within
the MMP-family, to elucidate how and when it is expressed and how its catalytic activity is
regulated. To gain information on its essential functions and substrates, the specific aim was
to characterize how epilysin affects the phenotype of epithelial cells, where it is biologically
expressed.
Applying different promoter analysis techniques we found that the epilysin promoter
contains a well conserved GT-box that is essential for the basic expression of this gene.
Transcription factors Sp1 and Sp3 bind this sequence and could hence regulate both the basic
and cell type and differentiation stage specific expression of epilysin. We cloned mouse
epilysin cDNA and found that epilysin is well conserved between human and mouse genomes
and that epilysin is glycosylated and activated by furin. RNA-analysis revealed that epilysin,
similarly to in human tissues, is normally expressed in a number of mouse tissues. The
expression pattern differs from most other MMPs, which are expressed only in response to
injury or inflammation and in pathological processes like cancer. These findings implicate
that epilysin could be involved in tissue homeostasis, perhaps fine-tuning the phenotype of
epithelial cells according to signals from the ECM.
In view of these results, it was unexpected to find that epilysin can induce a stable
epithelial to mesenchymal transition (EMT) when overexpressed in epithelial lung carcinoma
cells. Transforming growth factor b (TGF-b) was recognized as a crucial mediator of this
process, which was characterized by the loss of E-cadherin mediated cell-cell adhesion,
elevated expression of gelatinase B and MT1-MMP and increased cell migration and invasion
into collagen I gels. We also observed that epilysin is bound to the surface of epithelial cells
and that this interaction is lost upon cell transformation and is susceptible to degradation by
membrane type-1-MMP (MT1-MMP). The wide expression of epilysin under physiological
conditions implicates that its effects on epithelial cell phenotype in vivo are not as dramatic as
seen in our in vitro cell system. Nevertheless, current results indicate a possible interaction
between epilysin and TGF-b also under physiological circumstances, where epilysin activity
may not induce EMT but, instead, trigger less permanent changes in TGF-b signaling and cell
motility. Epilysin may thus play an important role in TGF-b regulated events such as wound
healing and inflammation, processes where involvement of epilysin has been indicated.
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1 Introduction
1.1 Extracellular matrix
All tissues are formed of individual cells that are held together by the surrounding ECM
(Aumailley and Gayraud, 1998; Zagris, 2001). The molecules of the ECM not only confer
mechanical support as they also interact with the cells to regulate cell adhesion and guide cell
migration. In addition, the ECM functions as storage for signaling molecules, growth factors
and enzymes modulating their activity and availability. The ECM thus provides a dynamic
environment for the cells embedded within and plays a key role in determining cell phenotype
(Streuli, 1999).
The ECM is a complex structure consisting of numerous components. As the ECM
proteins are produced by the cells it harbors such as fibroblasts, osteoblasts, and macrophages,
the composition and architecture of the ECM varies largely between different tissues
(Aumailley and Gayraud, 1998). ECM can structurally be divided into two major
components, the interstitial matrix and the basement membrane (BM).
1.1.1 Interstitial matrix
The interstitial matrix is formed by a network of fibers surrounded by a gel-like substance
containing glycosaminoglycans (GAGs), proteoglycans (PGs) and water that these molecules
hold. The most abundant structural components of the interstitial matrix are the collagens,
which are trimeric molecules containing three identical or different a-chains. The 43 different
a-chains can be combined in numerous different ways to form a wide variety of different
fibrillar and non-fibrillar collagen types, of which 28 different types have been identified to
date (Myllyharju and Kivirikko, 2004; Ricard-Blum and Ruggiero, 2005; Kadler et al., 2007).
The fibrillar collagens (types I, II, III, V, XI, XXIV and XXVI) typically consist of three a-
chains  containing  a  variable  number  of  Gly-X-Y  repeats  that  form  a  tight  triple-helix.  The
fibrillar collagens confer mechanical strength to tissues by assembling into large cross-linked
fibrils. The a-chains are synthesized and secreted as precursors with large N- and C-terminal
propeptides that prevent them from folding prematurely. The triple-helical structure is highly
resistant to proteolysis and degradation. Type I collagen is the most abundant collagen in
most connective tissues. It consists of two a1(I) and one a2(I) chain and is designated
[a1(I)]2a2(I). The tissue distribution of other fibrillar collagens is much more restricted.
The non-fibrillar collagens constitute a more heterogeneous group of molecules, and are
further divided into several subgroups based on their function, supramolecular assemblies or
other features (Myllyharju and Kivirikko, 2004; Ricard-Blum and Ruggiero, 2005; Kadler et
al.,  2007).  Of  the  network-forming  collagens  (types  IV,  VIII  and  X),  type  IV  is  the  major
component of BMs (see paragraph 1.1.2). The fibril-associated and related collagens (types
IX, XII, XIV, XVI, XIX, XX, XXI and XXII) do not form fibers by themselves but are found
attached to the surface of fibrils of the fibrillar collagens. In addition there are beaded-
filament-forming collagens (types VI, XXVI and XXVIII), which form microfibrils, and one
anchoring  collagen  (type  VII),  which  participates  in  the  attachment  of  BM  and  epithelia  to
underlying stroma. Collagens VI and VII are found in most connective tissues, whereas the
expression of collagens XXVI and XXVIII is more restricted. Further, there are collagens
with transmembrane domains (types XIII, XVII, XXIII and XXV), which participate in cell
adhesion. The closely related multiplexins (multiple triple-helix domain and interruptions,
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types XV and XVIII) are found in attachment to the BM. Proteolytic cleavage of the C-
terminal domain of collagen XVIII generates the antiangiogenic peptide endostatin (O´Reilly
et al., 1997; Wickström et al., 2005).
Some tissues like the lung and blood vessels, contain elastic fibers (Arribas et al.,
2006), which allow these tissues to endure stretch and pressure. The elastic fibers are
composed mainly of elastin that is first produced as a soluble precursor, tropoelastin, which is
then converted to highly insoluble elastin upon secretion from the cells (Mecham and Heuser,
1991). Elastin is extensively cross-linked to form stable fibers. These fibers are surrounded by
microfibrils constructed of fibrillin and other associated proteins, such as the latent TGF-b
binding proteins (LTBPs) (Hyytiäinen et al., 2004).
Various proteoglycans (PGs) are also important components of the interstitial ECM
They are highly hydrophilic and retain water and thus formi the amorphous ground substance
of the ECM (Iozzo, 1998). The PGs consist of a core protein attaching numerous sulfated
sugar chains, glycosaminoglycans (GAGs), which constitute the major part of the overall
weight of the PGs. In addition to retaining water, the PGs possess more specialized features.
They influence cell growth and maturation of specialized tissues, modulate growth factor
availability and binding of these to cognate receptors, and affect tumor cell growth and
invasion (Gesslbauer et al., 2007). For example, the heparan sulfate PGs bind several ECM
associated growth factors of the fibroblast growth factor (FGF) and vascular endothelial
growth factor (VEGF) families. Different cell types express different PGs, whose GAGs may
vary in response to growth factors during developmental and pathological processes. The
proteoglycanome, which is the entire subset of proteoglycans expressed in a tissue, thus plays
an active role in modulating cell phenotype and tissue composition and function.
Glycoproteins, another important group of ECM molecules, differ from the PGs in that
their carbohydrate component constitutes a much smaller proportion of the overall molecule.
One of the most abundant glycoproteins is fibronectin (Ruoslahti and Vaheri, 1974), which is
a large glycoprotein containing two disulfide linked subunits of 250-280 kDa each.
Fibronectin is located in fibrillar structures, especially in provisional matrices during wound
healing, but is also widely distributed in soluble form in the plasma. Fibronectin interacts with
numerous proteins on the cell surface as well as in the ECM (Magnusson and Mosher, 1998).
1.1.2 Basement membrane
BMs form highly specialized sheets of ECM proteins that separate epithelial and endothelial
cells from the underlying stromal tissue. In addition to serving as an adhesion interface
between these different compartments, the BM also functions as a permeability barrier and
controls cell organization and differentiation through interactions with cell surface receptors
and ECM proteins (Masunaga, 2006). The major structural component of the BM is collagen
IV, which is a heterotrimer that forms flexible helical rods with interruptions. The most
common structure of collagen IV is [a1(IV)]2a2(IV), but six different a-chains have been
identified that can be combined into a number of different trimers (Hudson et al., 2003). The
trimers self-assemble through different forms of intra and intermolecular interactions into a
highly cross linked network that confers mechanical stability to the BM  (Timpl, 1996).
The most abundant glycoproteins of the BM are laminins, which are formed through the
association of three genetically different polypeptides, the a, b and g chains. Five a, four b
and three g peptides have been identified, which can associate to form at least 15 different
heterotrimers that form cross-shaped molecules with three short arms (Patarroyo et al., 2002;
Miner and Yurchenco, 2004). In the presence of calcium, laminin I self-assembles into a
polymeric scaffold that is further connected to the collagen IV network via the glycoprotein
13
nidogen. Nidogen further interacts with other glycoproteins like fibulin and the abundant BM
proteoglycan perlecan (Aumailley and Gayraud, 1998).
1.1.3 Interactions between cells and the ECM
The components of the ECM are in constant interaction with the surrounding cells. ECM can
affect cell behavior either through the growth factors that it harbors or through direct
interactions between ECM molecules and cell surface receptors (Nelson and Bissell, 2006).
The major cell surface receptors mediating cell adhesion to ECM proteins are the integrins
(Hynes, 2002). In addition to binding ECM proteins in the extracellular compartment,
integrins also form transmembrane contacts with intracellular proteins and the cytoskeleton.
The integrins consequently transmit signals in two directions to coordinate the intracellular
environment with extracellular signals, and in this way play critical roles in numerous
biological as well as pathological processes. The integrins are heterodimers formed by
noncovalent association of an a and a b subunit. In mammals 18 a subunits and 8 b subunits
have been identified that can be combined to form over 20 different integrins with specific
tissue distribution and ligand preferences (Heino, 2000; Hynes, 2002).
During embryonic development the interactions between embryonic cells and their
ECM initiate and guide developmental processes, such as cell migration, morphogenesis, and
modulation of growth and differentiation pathways (Zagris, 2001). In adult tissues the
interplay between cells and the ECM is more stable emphasizing cell adhesion and restraining
cell migration, which is important for tissue homeostasis and organ function (Geiger et al.,
2001). An important ECM molecule promoting cell adhesion is fibronectin (Ruoslahti and
Vaheri, 1974; Magnusson and Mosher, 1998). Its adhesive activity has been traced to an RGD
(Arg-Gly-Asp) sequence commonly found also in other ECM molecules functioning in cell
adhesion, such as tenascin and laminin I (Aumailley and Gayraud, 1998).
During tissue level processes such as inflammation, wound healing and metastasis,
novel signals are generated from the ECM and new epitopes exposed within the surrounding
tissues. These induce the cells to react properly to the new circumstances (Gustafsson and
Fässler, 2000). The ability of any cell to remodel the ECM is therefore critical for interactions
with its surroundings and, on a larger scale, for any organism to function properly (Vu and
Werb, 2000; Sternlicht and Werb, 2001; Stamenkovic, 2003). Numerous proteases have been
implicated in the remodeling and degradation of the ECM. These can be categorized either as
exopeptidases that cleave their substrates at terminal sites or as endopeptidases that cleave at
internal sites. Based on their catalytic mechanism endopeptidases can be divided into four
major classes: serine, cysteine, aspartic and metalloproteinases. Most of the
metalloproteinases take advantage of zinc for their catalytic activity. This large family is
further divided into subfamilies, one of which is the metzincins, which contains the family of
matrix metalloproteinases (MMPs) (Woessner, 1998).
1.2 Matrix Metalloproteinases
The first evidence of a soluble enzyme capable of degrading native collagen came from
experiments, where tissue fragments of involuting tadpole tails were cultured on native
collagen gels (Gross and Lapiere, 1962). Since then a family of 24 human endopeptidases
capable of degrading most ECM components, as well as several cell surface and pericellular
proteins, has been identified (Sternlicht and Werb, 2001). MMPs not only possess the means
to degrade ECM, but also to release bioactive fragments and growth factors, thus influencing
fundamental biological and pathological processes like embryonic development, tissue
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morphogenesis, wound repair, inflammation and cancer (Egeblad and Werb, 2002; Mott and
Werb, 2004). All MMPs have distinct but partially overlapping functions (Sternlicht and
Werb, 2001). The reason for this redundancy may be to protect the organism from the loss of
regulatory control, as MMPs participate in such a wide variety of essential processes. This has
become evident through the generation of genetically modified mice lacking specific Mmp
genes. Many of these animals exhibit an unexpectedly mild phenotype, compared to what
could be expected from the knowledge of their in vitro substrates (Table II).
1.2.1 Structures and substrates of the different MMP subfamilies
MMPs share a common domain structure and catalytic mechanism (Nagase et al., 2006). All
MMPs are extracellular proteins containing an N-terminal signal sequence that targets them
for secretion. The signal sequence is followed by a propeptide containing a conserved
PRCGXPD sequence and the catalytic domain that contains a conserved HEXXHXXGXXH
sequence. This sequence includs three histidine residues that together bind a zinc ion critical
for the catalytic activity. Before removal of the propeptide its conserved cysteine residue also
interacts with this zinc ion, preventing catalytic activity. This mechanism has been named the
“cysteine switch” (Van Wart and Birkedal-Hansen, 1990). Specific amino acids within the
catalytic domain define substrate specificity by allowing interactions with a limited subset of
substrates only (Visse and Nagase, 2003). Substrate specificity is further determined by
substrate binding sites located outside the catalytic domain named exosites. The catalytic
domain in most MMPs is followed by a proline-rich linker, the hinge region. This is further
attached to the C-terminal hemopexin domain, which functions in substrate and inhibitor
interactions. Exceptions are the matrilysins MMP-7 (Muller et al., 1988) and MMP-26 (Park
et al., 2000) that lack the hemopexin domain, and MMP-23 which contains C-terminal
cysteine- and proline-rich domains and a domain resembling the interleukin (IL)-1 type II
receptor instead of the hemopexin domain (Pei, 1999a; Velasco et  al., 1999). In addition to
the common domains, MMPs contain a number of more specialized structures. Based on these
specific characteristics and substrate preference, MMPs can be further divided into
subfamilies (Fig. 1, Table I).
Figure 1. Domain structures of the MMP subfamilies. Abbreviations: SS, signal sequence; PRO, propeptide;
Catalytic, catalytic domain; H, hinge region; Hemopexin, hemopexin domain; Fn, fibronectin type II inserts; F,
furin-cleavage site; TM, transmembrane domain; Cyt, cytoplasmic domain; GPI, glycosylphosphatidyl inositol-
anchoring domain; Vn, vitronectin-like sequence; CA, cysteine array; Ig, immunoglobulin-like domain.
Modified from Sternlicht and Werb, 2001; Ala-aho and Kähäri, 2005.
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Table I. Substrates of human MMPs. MMPs are listed together with their common names. DS: domain
structure (refers to DS outlined in Fig. 1). Some substrates are listed in the right column.
Name DS Substrates
MMP-1 collagenase-1 B col I-III VII VIII X XI, aggrecan, gelatin, fibronectin, laminin,
nidogen, IGFBPs, tenascin, vitronectin, fibrin, fibrinogen, casein, pro-
TNFa, IL-1b, a1-PI, a2-M, pro-MMP-1 and -2.
MMP-2 gelatinase A C col I III-V VII X XI, aggrecan, elastin, fibrillin, fibronectin, gelatin,
nidogen, IGFBPs, laminin, tenascin, vitronectin, a1-PI, a2-M, fibrin,
fibrinogen, IL-1b, pro-TGFb, pro-TNF-a, plasminogen, pro-MMP-9,
and -13, dystroglycan.
MMP-3 stromelysin-1 B col III-V VII X XI, elastin, aggrecan, nidogen, fibrillin, fibronectin,
gelatin, IGFBPs, laminin, tenascin, vitronectin, a1-PI, a2-M, E-
cadherin, fibrin, fibrinogen, casein, IL-1b, pro-TNF-a, plasminogen,
uPA, pro-MMP-1, -2, -8, -9, and -13.
MMP-7 matrilysin A col I IV, aggrecan, elastin, nidogen, gelatin, fibronectin, laminin,
tenascin, vitronectin, E-cadherin, pro-a-defensin, fibrinogen, casein,
pro-TNF-a, plasminogen, a1-PI, Fas-ligand, syndecan-1, pro-MMP-1,
-2, and -9.
MMP-8 collagenase-2 B col I-III, aggrecan, a1-PI, a2-M, fibrinogen, pro-MMP-8.
MMP-9 gelatinase B C col IV V XI XIV, aggrecan, elastin, fibrillin, gelatin, laminin,
vitronectin, a1-PI, a2-M, fibrin, fibrinogen, casein, IL-1b, pro-TGFb,
pro-TNF-a, plasminogen, E-cadherin, dystroglycan.
MMP-10 stromelysin-2 B col III-V, aggrecan, elastin, fibronectin, gelatin, fibrinogen, casein,
laminin-5, pro-MMP-1, -2, -8, and -13.
MMP-11 stromelysin-3 D IGFBPs, a1-PI, a2-M.
MMP-12 metalloelastase B col I IV, aggrecan, elastin, nidogen, fibrillin, fibronectin, gelatin, a1-
PI, a2-M, fibrinogen, pro-TNF-a, plasminogen, pro-MMP-2.
MMP-13 collagenase-3 B col I-III VI IX X XIV, aggrecan, fibrillin, fibronectin, gelatin, a2-M,
fibrinogen, casein, pro-MMP-2, -9, and -13.
MMP-14 MT1-MMP E col I-III, aggrecan, fibrillin, fibronectin, nidogen, gelatin, laminin,
vitronectin, a1-PI, a-2M, fibrin, fibrinogen, pro-TNF-a, CD44, aV
integrin, syndecan-1, EMMPRIN, E- and N-cadherins, ICAM-1, pro-
MMP-2, and -13.
MMP-15 MT2-MMP E col I, fibrinogen, pro-MMP-2, and -13.
MMP-16 MT3-MMP E col III, fibronectin, pro-MMP-2.
MMP-17 MT4-MMP F gelatin, fibrinogen, fibrin, pro-TNF-a, ADAMTS4.
MMP-19 RASI B col I IV, fibronectin, gelatin, IGFBPs, tenascin, casein.
MMP-20 enamelysin B amelogenin.
MMP-21 XMMP G a1-PI.
MMP-23 H
MMP-24 MT5-MMP E gelatin, pro-MMP-2.
MMP-25 MT6-MMP F col IV, gelatin, fibrin, fibronectin, chondroitin sulfate proteoglycan,
dermatan sulfate proteoglycan, a1-PI.
MMP-26 matrilysin-2 A col IV, fibronectin, gelatin, fibrinogen, a1-PI, pro-MMP-9.
MMP-27 B casein, gelatin.
MMP-28 epilysin D casein, NCAM.
Col denotes collagen; a1-PI, a1-proteinase inhibitor; a2-M, a2-macroglobulin; IL-1b, interleukin-1b; uPA,
urokinase-type plasminogen activator. Based on Vu and Werb, 2000; English et al., 2001; Sternlicht and Werb
2001; Ala-aho and Kähäri, 2004; Gao et al., 2004; Krampert et al., 2004; Wielockx et al., 2004; Agrawal et al.,
2006; Covington et al. 2006; Egawa et al., 2006; Itoh and Seiki, 2006; Sithu et al.,2007; Symowicz et al., 2007;
Werner et al., 2007.
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Accordingly, MMPs also share a similar gene arrangement suggesting that they have
evolved from a common ancestor gene. At least eight of the known human Mmp genes are
clustered on chromosome 11 at 11q21-23.
1.2.1.1 Collagenases
Collagenases 1-4 cleave interstitial collagens I, II and III into two fragments comprising 3/4
and 1/4 of the molecule, respectively (Jeffrey, 1998). The different collagenases, however,
have different substrate preferences as collagenase-1 preferentially cleaves collagen III
whereas collagenase-2 prefers collagen I. The collagenases also digest a number of other
ECM components and other molecules (Table I, Sternlicht and Werb, 2001).
Collagenase-1 (MMP-1) is the founding member of the MMP-family (Gross and
Lapiere, 1962). The protein and the cDNA were originally identified and purified from human
skin fibroblasts (Stricklin et al., 1977; Goldberg et al., 1986), but in vitro the enzyme is also
secreted by other fibroblasts, chondrocytes, osteoblasts, endothelial cells and tumor cells,
among others (Ala-aho and Kähäri, 2005). Collagenase-2 (MMP-8) has also been named
neutrophil collagenase as it is synthesized by neutrophils during their maturation in bone
marrow and stored in specific granules within the cells, from where the enzyme can be
released upon external signals (Hasty et al., 1990). Collagenase-2 is also expressed in human
articular cartilage, in rheumatoid synovium and during bronchitis (Ala-aho and Kähäri, 2005).
Collagenase-3 (MMP-13) preferentially cleaves collagen II found in cartilage but has also
strong gelatinolytic activity. It has been implicated in biological processes like organ
development as well as in pathological processes related to chronic wounds and cancer (Ala-
aho and Kähäri, 2005). Collagenase IV (MMP-18) is expressed only in Xenopus laevis
(Stolow et al., 1996).
The individual roles of the collagenases in rodents differ from those in humans. The
primary interstitial collagenases of these animals show highest homology to human
collagenase-3 instead of the major human collagenase, collagenase-1. The expression profiles
of mouse and rat collagenase-3 are, however, highly similar to that of human collagenase-1,
indicating that these MMPs are functional homologues. Two closely related mouse
counterparts to human collagenase-1, Mcol-A and Mcol-B, have been cloned (Balbín et al.,
2001). Their expression is, however, restricted to embryo implantation and only Mcol-A is
able to cleave collagen I.
1.2.1.2 Gelatinases
The gelatinases act on a large number of substrates including collagens, elastin, fibronectin
and denatured collagen, gelatin. In addition, they cleave numerous non-ECM molecules in
vitro (Table I, Sternlicht and Werb, 2001). The enzymes are distinguished by three head-to-
tail repeats of a type II fibronectin domain in their catalytic domains (Fig. 1), which are
required for the gelatinases to bind and digest collagens and elastin (Murphy et al., 1994;
Shipley et al., 1996). Gelatinase A (MMP-2) differs from most other MMPs in the sense that
it is expressed constitutively by numerous normal and transformed cells and has ubiquitous
tissue distribution (Yu et al., 1998). The expression of gelatinase B (MMP-9) is more
restricted. It is produced by neutrophils and stored within secretory granules, from where the
enzyme can be released upon demand. Gelatinase B is also secreted by macrophages and
various tumors and transformed cell lines and mostly maintained at low levels in normal
tissues (Vu and Werb, 1998). Both gelatinases are, however, frequently upregulated in
different forms of cancers, especially during tumor metastasis (Egeblad and Werb, 2002;
Deryugina and Quigley, 2006).
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1.2.1.3 Stromelysins
The domain structure of the stromelysins resembles that of the collagenases (Fig. 1), but they
cannot cleave interstitial collagens. Stromelysins 1 (MMP-3) and 2 (MMP-10) are similar in
structure and substrate specificity, whereas stromelysin-3 (MMP-11) differs from these two in
both aspects. Stromelysins 1 and 2 degrade numerous ECM proteins and participate in the
activation of other MMPs (Table I, Sternlicht et al., 1999). Stromelysin-3 shows only weak
activity towards most ECM proteins in vitro but, instead, cleaves and inactivates proteinase
inhibitors (Pei et al., 1994) and insulin-like growth factor binding protein-1 (IGFBP-1)
(Manes et al., 1997). Stromelysin-3 contains an RXKR sequence at the end of the prodomain,
which serves as a recognition site for the proprotein convertase furin, enabling intracellular
activation of the enzyme (Pei and Weiss, 1995).
1.2.1.4 Matrilysins
Matrilysins are the smallest MMPs since they lack the hemopexin domain. Matrilysin (MMP-
7) is synthesized by epithelial cells and is secreted apically. Matrilysin is, unlike most other
MMPs, expressed in normal adult tissues (Wielockx et al., 2004) and it cleaves a large variety
of both collagens and other ECM proteins in vitro (Table I). Matrilysin activates intestinal
crypt a-defensins, which are anti-microbial peptides that participate in the innate immune
system of the intestine (Table II, Wilson et al., 1999). Matrilysin also cleaves important cell
surface adhesions receptors like E-cadherin (Noë et al., 2001), implicating its role in cell
migration (McGuire et al., 2003). Matrilysin is further frequently expressed in different forms
and stages of cancer and in inflammatory disorders (Wielockx et al., 2004).
Endometase (matrilysin-2, MMP-26), which digests several ECM proteins, is expressed
in normal endometrium and in some tumors (Park et al., 2000; Uria and Lopez-Otin, 2000).
Endometase differs form all other MMPs in the respect that it contains an estrogen-response
element in the promoter and can be induced in hormone regulated carcinomas (Li et al.,
2004b).
1.2.1.5 Membrane-type MMPs
Four of the MMPs, namely MT1-, MT2-, MT3-, and MT5-MMP (MMPs 14, 15, 16 and 24)
have a C-terminal transmembrane domain and a short intracellular tail, which target them to
the cell membrane (Fig. 1). MT4- and MT6-MMP (MMPs 17 and 25) are attached to the cell
surface by C-terminal glycosylphosphatidylinositol (GPI) anchors (Fig. 1). All MT-MMPs
contain a furin recognition sequence in the C-terminus of their propeptides allowing
intracellular activation.
MT1-MMP (Sato et al., 1994) digests numerous substrates including collagens and
several ECM proteins, as well as proteinase inhibitors, cell surface receptors and growth
factors (Table I). MT1-MMP has been widely implicated in numerous physiological and
pathological processes including development, promotion of cell motility and invasion,
angiogenesis, cancer and rheumatoid arthritis (Holmbeck et al., 2004; Itoh and Seiki, 2006).
MT1-MMP can also activate gelatinase A by proteolytic removal of its prodomain (Strongin
et al., 1995). MT2-MMP (Will and Hinzmann, 1995) is expressed in a number of human
tissues and in various forms of cancer, where its expression correlates with increased
invasiveness. Like MT1-MMP, it degrades collagen I, fibrinogen and numerous other ECM
proteins (Table I). MT2-MMP is also able to activate gelatinase A by a mechanism different
from that of MT1-MMP (Morrison et al., 2001). MT3-MMP (Takino et al., 1995) is generally
expressed at lower levels than MT1- and MT2-MMP. The enzyme can cleave progelatinase
A, but is not involved in type I collagen invasion in vitro (Hotary et al., 2000). Importantly,
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MT1-, MT2- and MT3-MMP are the proteases that, independent of each other, confer cancer
cells with the ability to degrade and invade through BMs in vivo, a critical event in cancer
metastasis (Hotary et al., 2006). MT5-MMP is predominantly expressed in the hippocampus
and in cerebellum where it possibly promotes axon and dendrite extension (Llano et al., 1999;
Pei, 1999b).
MT4- (Puente et al., 1996) and MT6-MMP (Pei, 1999c; Velasco et  al., 2000) differ
from the other MT-MMPs in the sense that they are inefficient in cleaving progelatinase A
and many ECM components. MT4-MMP has been detected in neurons in the cerebrum,
smooth muscle cells and macrophages (Rikimaru et al., 2007), but also in several human
cancers. MT4-MMP is involved in the activation of the metalloproteinase ADMTS4 (a
disintegrin-like and metalloproteinase domain with trombospondin motifs-4) in vitro (Gao et
al., 2004) and overexpression of MT4-MMP in breast cancer cells promotes primary tumor
growth and metastasis in vivo (Chabottaux et al., 2006). MT6-MMP is predominantly
expressed in leukocytes but also in some forms of cancers. It promotes tumor growth and
invasion of colon carcinomas in vivo (Sun et al., 2007).
MMP-23 has a unique domain structure among the MMPs as it lacks a hemopexin
domain but, instead, contains C-terminal cysteine- and proline-rich domains and a domain
resembling the IL-1 type II receptor (Fig. 1) (Pei, 1999a; Velasco et al., 1999). Unlike all
other MMPs, MMP-23 is a type II transmembrane protein as it contains an N-terminal signal
anchor (Pei et al., 2000). MMP-23 is predominantly expressed in ovary, testis and prostate
(Velasco et al., 1999), but its functions are largely unknown.
1.2.1.6 Other MMPs
Six human MMPs do not belong to any of the groups above. Metalloelastase (MMP-12)
digests elastin and numerous other ECM proteins as well as other molecules such as proTNF-
a (Table I). In vivo, metalloelastase is involved in the generation of angiostatin (Dong et al.
1997; Cornelius et al. 1998), an inhibitor of angiogenesis that is derived by proteolytical
cleavage of plasminogen. Metalloelastase is expressed primarily in macrophages and has been
implicated in inflammatory skin and pulmonary diseases and cancer (Nenan et al., 2005).
MMP-19 (RASI) is expressed in several normal human tissues (Cossins et al., 1996;
Pendas et  al., 1997) and can digest many ECM components in vitro, including various
components  of  the  BM  (Table  I;  Stracke et  al., 2000). Unlike most other MMPs, it is
expressed in basal keratinocytes in the healthy epidermis, but is upregulated also in the
suprabasal layers in diseases such as psoriasis (Sadowski et al., 2003b; Suomela et al., 2003).
In wounds, it is expressed in keratinocytes outside the migrating area. In skin cancers MMP-
19 is expressed in hyperproliferative epidermis but not in invading cells (Impola et al., 2003).
MMP-19 increases cellular proliferation as well as migration and adhesion to collagen I in
vitro through the cleavage of IGFBP-3 and subsequent release of insulin-like growth factor
(IGF) (Sadowski et  al., 2003a). Further, MMP-19 is downregulated by the transcription
factors Tst-1 and Skn-1 that promote keratinocyte differentiation and decrease proliferation
(Beck et al., 2007).
The expression of enamelysin (MMP-20) is highly restricted to dental tissues (Llano et
al., 1997). It degrades amelogenin, a major protein component of the enamel matrix and is
essential for proper enamel development (Caterina et al., 2002).
MMP-21 (XMMP) was originally cloned from Xenopus laevis and is a secreted protease
with a furin recognition site (Yang et al., 1997). Its human homologue is expressed in a
number of fetal and adult tissues and in some carcinomas (Ahokas et al., 2002). In basal and
squamous cell carcinomas it is expressed in invasive cancer cells (Ahokas et al., 2003).
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MMP-27 was originally cloned from chicken embryonic fibroblasts (Yang and
Kurkinen, 1998). Chicken MMP-27 digests casein and gelatin in vitro, but its mammalian
homologue is poorly characterized (Clark et al., 2003).
1.2.2 Targeted disruption of Mmp genes in the mouse
To date, at least 15 mouse models have been generated where specific Mmp genes have been
deleted. Most of these have shown unexpectedly subtle phenotypes, and all survive until birth.
It is possible that the MMPs are dispensable for embryonic development, but the explanation
may also be found in enzymatic redundancy or compensation, as has been indicated by the
generation of MMP double mutants  (Table II; Page-McCaw et al., 2007).
The generation of MT1-MMP deficient mice directed much interest towards this
enzyme. This is the only Mmp knock-out (KO) mouse generated so far exhibiting a major
phenotype, one much more severe than what have been observed by deleting genes coding for
soluble Mmps (Table II). The Mt1-mmp KO  mice  showed  sever  developmental  defects  in
bone formation and angiogenesis, mostly due to lack of collagenolytic activity (Holmbeck et
al., 1999; Zhou et  al., 2000). Gelatinase A deficient mice, on the contrary, exhibit a mild
phenotype (Itoh et al., 1997) with no resemblance to the much more severe phenotype of Mt1-
mmp deficient mice. These results indicate that collagen degradation, but not activation of
progelatinase A, is a critical function of MT1-MMP in vivo. Gelatinase A and Mt1-mmp
double KO mice, however, display severe defects in blood vessels and muscle fibers, and die
immediately after birth due to respiratory failure (Oh et al., 2004).
The mice deficient in gelatinases A and B, collagenase-3, enamelysin and the TIMPs
have subtle phenotypes that emerge over time during the lifespan of the animals.
Interestingly, these mouse models reveal that even though the MMPs are dispensable for the
development of blood vessels and bone in the embryo, they are required for the postnatal
development and remodeling of these tissues (Page-McCaw et al., 2007).
Deletion of other Mmp genes has not generated obviously altered phenotypes. However,
the lack of other Mmp genes results, in many cases, in altered reactions to specific pathogenic
challenges revealing functions for these MMPs in disease progression, inflammation and
regenerative processes (Fingleton, 2007). The matrilysin deficient mice, for example, fail to
activate intestinal crypt a-defensins, making these mice more susceptible to bacterial
infection (Wilson et al., 1999). Upon lung injury, the influx of neutrophils into the alveolar
space of these mice is also reduced due to lack of release of chemotactic chemokines (Li et
al., 2002). Further, tracheal wounds of these mice re-epithelialize more slowly. This defect is
a consequence of the inability of tracheal epithelial cells to migrate over the wound area due
to the lack of E-cadherin processing (McGuire et al., 2003).
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Table II. Phenotypic characteristics of Mmp and Timp deficient mice.
Gene Mouse phenotype
Mmp-2 Reduced body size; reduced neovascularization; delayed mammary gland development;
reduced lung saccular development; decreased allergic inflammation.
Mmp-3 Altered structure of neuromuscular junctions; delayed wound healing; hypomorphic
mammary gland development.
Mmp-7 Decreased re-epithelialization after lung injury; innate immunity defects; decreased
movement of neutrophils and chemokines upon injury and inflammation; reduced shedding of
Fas-ligand and epithelial cell apoptosis.
Mmp-8 Increased skin tumors; delayed neutrophil recruitment to dermis surrounding skin tumors;
resistance to TNF-induced lethal hepatitis.
Mmp-9 Bone-development defects; defective neuronal remyelination after nerve injury; delayed
healing of bone fractures; impaired vascular remodeling; impaired angiogenesis; altered
chemokine and neutrophil movement upon injury and inflammation; enhanced airway
inflammation in allergic lung inflammation.
Mmp-10 Enhanced pneumonia upon bacterial infection.
Mmp-11 Delayed mammary tumorigenesis; reduced mammary carcinogenesis upon carcinogen
treatment.
Mmp-12 Diminished recovery from spinal cord injury; increased angiogenesis due to decreased
angiostatin; resistance to cigarette smoke-induced emphysema; reduced movement of
neutrophils and chemokines upon injury and inflammation.
Mmp-13 Bone remodeling defects; reduced hepatic fibrosis; increased collagen accumulation in
atherosclerotic plaques; attenuated inflammatory reaction during cholestasis.
Mmp-14 Skeletal remodeling defects; angiogenesis defects; inhibition of tooth eruption and root
elongation; defects in lung and submandibular gland; inadequate collagen turn-over and early
postnatal death.
Mmp-17 No detected phenotype.
Mmp-19 Obesity; early onset of tumor angiogenesis.
Mmp-20 Defects in tooth enamel.
Mmp-24 Abnormal response to sciatic nerve injury.
Mmp-2 and
Mmp-9
Complete inhibition of tumor vascularization and growth; resistance to experimental
autoimmune encephalomyelitis due to lack of dystroglycan cleavage and leukocyte infiltration
through the blood-brain barrier.
Mmp-2 and
Mmp-3
No detected phenotype.
Mmp-2 and
Mmp-14
Immediate postnatal death with respiratory failure, abnormal blood vessels and immature
muscle fibers.
Mmp-9 and
Mmp-13
Severely impaired endochondral bone formation.
Timp-1 Accelerated endometrial gland formation; impaired learning and memory; accelerated
hepatocyte cell-cycle progression; increased resistance to bacterial infection.
Timp-2 Motor defects; deficient MMP-2 activation.
Timp-3 Accelerated apoptosis in mammary gland; impaired bronchiole branching; enhanced
metastatic dissemination; increased cartilage degradation with age; deficient innate immunity.
Based on Sternlicht and Werb, 2001; Oh et al., 2004, Stickens et al., 2004; Masson et al., 2005; Agrawal et al.,
2006; Jost et al., 2006; Kassim et al., 2007; Manicone and McGuire, 2007; Page-McCaw et al., 2007; Rikimaru
et al., 2007.
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1.2.3 Epilysin (MMP-28)
Epilysin (MMP-28) is the most recently cloned member of the MMP-family. It was originally
cloned from human keratinocyte and testis cDNA libraries (Lohi et al., 2001), and also from
lung cDNA (Marchenko and Strongin, 2001).
Figure 2. Amino acid sequence and domain structure of human epilysin. The amino acid sequence of
epilysin is given in the one-letter code. Different protein domains are indicated above the sequence and the
border between adjacent domains by ¨. The pro-sequence PRCGVTD, the zinc-binding sequence
HEIGHTLGLTH and the furin-recognition sequence RKKR are indicated with a black background, as well as
the conserved YGYL sequence in the prodomain. Two potential N-glycosylation sites are underlined. Numbers
on the left indicate the positions of amino acids (Lohi et al., 2001).
The cDNA contains an open reading frame of 1560 nucleotides coding for a 520-aa
protein. The protein contains all the typical MMP domains; a hydrophobic signal sequence is
followed by the prodomain including a PRCGVT-sequence. A furin recognition site RKKR is
present in the C-terminal end of the prodomain. This sequence serves as a target for the furin-
family of proprotein convertases that are membrane bound serine proteases, both in the trans-
Golgi network and at the cell surface (Bassi et al., 2005). Similar sequences are found in all
the MT-MMPs but of the soluble MMPs only stromelysin-3 contains it (Pei and Weiss, 1995).
The following catalytic domain is typical for soluble MMPs, but the catalytic sequence
HEIGHTLGLTH is unique as no other MMP contains threonine within this sequence. A 39-
aa hinge region is followed by a typical hemopexin domain (Fig. 2).
Comparison of the amino acid sequence of epilysin with the other MMPs indicates that
epilysin is most closely related to another relatively new member, MMP-19 (Fig. 3, Lohi et
al., 2001). The epilysin gene is located on chromosome 17 (17q11.2), a locus that differs from
all other reported Mmp genes (Marchenko and Strongin, 2001). Epilysin has a unique
structural  gene  organization  as  it  consists  of  eight  exons  instead  of  ten,  which  is  typical  for
Mmp genes (Lohi et al., 2001). Stromelysin-3 is the only other Mmp gene with eight exons
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(Anglard et al., 1995), but overall the organization of the epilysin gene most closely
resembles that of Mmp-19 (Mueller et al., 2000).
Figure 3. Dendogram of the catalytic domains of
human MMPs. The amino acid sequences of the
catalytic domains of human MMPs were retrieved
from GenBankTM and aligned with ClustalW to
generate a phylogenetic tree. Epilysin is most
closely related to MMPs 19, 23, 11, and 17 (Lohi et
al., 2001).
Among human tissues, epilysin
mRNA is highly expressed in the testis and
at lower levels in the lung, heart, colon,
intestine and brain (Lohi et al., 2001), and
also in several fetal tissues and in the adult
kidney and pancreas (Marchenko and
Strongin, 2001). In the rat, higher levels of
epilysin mRNA were detected by real time
PCR in the bone, kidney and placenta, but
not in testis (Bernal et al., 2005), pointing
at differences in the mRNA expression
between species. When specific cell types
from these tissues were analyzed, epilysin
expression was detected only in primary
human keratinocytes grown on collagen
and in transformed HaCaT keratinocytes.
Epilysin protein was detected in the
conditioned medium of HaCaT
keratinocytes as a prominent 58 kDa band and a less prominent 55 kDa band by SDS-PAGE
and immunoblotting, indicating that the epilysin mRNA codes for a secreted protein.
Recombinant epilysin protein containing only the pro and catalytic domains digested casein in
vitro. This proteolytic activity could be inhibited by both EDTA and the specific MMP-
inhibitor batimastat, indicating that epilysin is a true MMP (Lohi et al., 2001). The wide
expression of epilysin in a number of normal tissues suggests that it may function in tissue
homeostasis.
1.2.3.1 Epilysin in wound healing
Because of the initial findings of epilysin in keratinocytes, its expression has been carefully
analyzed in human skin and during wound healing. The distribution of epilysin in the intact
human epidermis was visualized by immunohistochemical staining, demonstrating
progressively decreasing expression in the suprabasal layers. In dermal wounds, epilysin was
detected in stationary keratinocytes at a distance from the wound edge, but also in migrating
keratinocytes at the wound edge (Lohi et al., 2001). In contrast, in another study no epilysin
was detected in normal human skin. Epilysin was, however, detected in basal, proliferating
keratinocytes further away from the wound edge coinciding with the area where the type IV
collagen of the BM started to show an intact pattern, but not in migrating keratinocytes at the
wound edge (Saarialho-Kere et al., 2002). This discrepancy may reflect differences between
experimental  models.  The  results,  however,  suggested  that  epilysin  could  play  a  role  in
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epithelial cell proliferation or that it may be needed to restructure the newly formed BM
during wound repair.
Analysis of hypertrophic burn scars revealed that mechanical compression, a method
often used in the clinical treatment of this condition, markedly upregulated the expression of
epilysin (Reno et al., 2005).
1.2.3.2 Epilysin in cancer
Enhanced expression of epilysin has been observed in numerous different forms of cancer, but
there are also several reports on the downregulation of epilysin in malignant cells. The roles
of epilysin in various forms of cancer seem to vary based on tumor type and stage of the
disease.  Epilysin mRNA has been detected in colon adenocarcinoma cells, ovarian carcinoma
cells and pancreatic adenocarcinoma cells in culture (Marchenko and Strongin, 2001). In a
microarray study including 715 human proteases the expression of epilysin was strongly
elevated in invasive ductal cell carcinomas (Overall et  al., 2004). In this study epilysin was
the only MMP that was significantly upregulated in the cancer tissue. Similarly, in a real time
RT-PCR study where the expression levels of all human MMPs in urothelial carcinoma
extracts were examined epilysin, gelatinase A, and MT1-MMP were highly expressed
(Wallard et  al., 2006). By laser capture microdissection of the frozen tumors, the authors
localized  the  expression  of  epilysin  to  the  stromal  compartment  of  the  tumors.  Epilysin
protein has also been detected in proliferating basal and suprabasal keratinocytes in grade I
squamous cell carcinomas (SCC), but not in aggressive cutaneous sclerosing basal or
squamous cell carcinomas of grades II and III (Saarialho-Kere et al., 2002). Epilysin mRNA
was also upregulated in breast carcinoma cells exhibiting increased proliferation due to
overexpression of stromelysin-3 (Kasper et al., 2007). In colon carcinomas, on the other hand,
epilysin was downregulated in the tumor epithelium (Bister et al., 2004), and no epilysin was
detected in melanoma cells (Kuivanen et al., 2005).
A functional role for epilysin has been described in oral squamous cell carcinomas
(OSCC) (Lin et al., 2006). Epilysin mRNA was markedly upregulated in OSCC samples as
compared to oral premalignant lesions. Capturing epilysin mRNA in OSCC and esophageal
carcinoma  cell  lines  with  antisense  oligodeoxynucleotides  reduced  the  secretion  of  epilysin
from  these  cells  as  well  as  the  ability  of  these  cells  to  form  colonies  in  soft  agar  without
affecting cell growth. These results indicate a role for epilysin in the anchorage-independent
growth of both OSCC and esophageal carcinomas.
1.2.3.3 Expression of epilysin in specialized tissues
Several studies imply the expression of epilysin in cartilage. For example, increased
expression of epilysin mRNA was detected by real-time PCR in the cartilage of patients
suffering from osteoarthritis (OA) (Kevorkian et al., 2004). Similarly, epilysin and also other
MMPs, were upregulated in the synovium of OA patients (Davidson et al., 2006). Epilysin is,
however, not very abundant in these tissues as the expression levels of collagenase-3 are
approximately 20-fold higher in OA cartilage. Similar results have been reported in studies
with cartilage from patients suffering from rheumatoid arthritis (Momohara et al., 2004).
These studies implicate that epilysin could be involved in the cartilage destruction involved in
both diseases. Interestingly, histone deacetylase (HDAC) inhibitors that regulate the
expression of several genes through modifying the acetylation of histones and consequently
the access of transcription factors to specific genes, block cartilage destruction in an ex vivo
model system (Young et  al., 2005). This repression was dependent on the decrease in the
expression of several members of the MMP-family, most importantly collagenases 1 and 3.
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On the contrary, other MMPs including epilysin were induced by HDAC inhibitors. The
authors suggest that HDAC inhibitors could be used as selective inhibitors of proteolysis in
OA, but the relevance of their ability to upregulate epilysin remained undefined. Further, the
expression  of  epilysin,  in  addition  to  other  MMPs,  has  been  detected  by  real  time  PCR  in
mesenchymal stem cells, where its expression was upregulated during chondrogenesis
(Djouad et al., 2007).
In a study on mRNA and protein expression in human skeletal muscle, the expression
level of epilysin mRNA was downregulated after 48 hours of immobilization, whereas the
protein levels remained unchanged (Urso et al., 2006). No significant changes in the levels of
other MMPs were detected, but TIMP-1 (tissue inhibitor of MMP) was similarly affected by
the procedure. The authors suggest that these results may have consequences in muscle
atrophy caused by immobilization.
 Further, two investigations concern the expression of epilysin in tissues related to
inflammation. Epilysin protein was detected in the apical regions of the villi in normal ileum
and colon, where the expression remained unaffected by inflammation (Bister et al., 2004).
Prominent expression of epilysin mRNA was, however, detected in T-lymphocytes where its
expression was decreased upon stimulation with phorbol-12,13-myristate and ionomycin
(Bar-Or et  al., 2003). The pro-inflammatory cytokine TNF-a has further been proposed to
induce the expression of epilysin in cell culture (Saarialho-Kere et al. 2002).
Expression of the epilysin homologue in Xenopus laevis was detected in neural tissues,
both in the central nervous system (CNS) and in peripheral nerves during later stages of
development (Werner et al., 2007). Expression of XMMP-28 was also detected in
regenerating nerves during the regeneration of Xenopus hindlimbs (King et al., 2003; Werner
et al., 2007), indicating that XMMP-28 serves a similar role in the neural system during
development and repair. The expression of XMMP-28 was downregulated when the process
of myelination was initiated both in vivo and in vitro, and in vitro XMMP-28 degraded the
neural cell  adhesion molecule NCAM. The authors speculate that XMMP-28 could alter the
neuronal microenvironment leading to the development of myelin, induce a more motile
phenotype in the glial cells or alter interactions between glial cells and axons by modifying
cell surface structures (Werner et al., 2007).
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1.2.4 Regulation of MMP activity
Because of the great potential of the MMPs to degrade the ECM and remodel or even destroy
tissues, their expression, activation, localization, inhibition and degradation are tightly
regulated processes allowing for control on multiple levels (Fig. 4).
Figure 4. Multiple levels of regulation of MMP activity. 1) activating and repressive signaling; 2) intracellular
signal transduction; 3) transcriptional activation and repression; 4) post-transcriptional mRNA processing; 5)
intracellular activation of furin-susceptible MMPs; 6) secretion; 7) proteolytic activation; 8) proteolytic
processing and degradation; 9) enzyme inhibition; 10) cell surface localization and anchoring; 11) ECM
localization; 12) endocytosis and intracellular degradation. Based on Sternlicht and Werb, 2001.
1.2.4.1 Transcriptional regulation
Because of the overlapping substrate specificity of many MMPs (Table I), the biological
functions of specific family members are largely determined by their individual expression
patterns. These are tightly regulated at the level of gene expression by individual, unique
combinations of transcriptional activators and repressors. With the exceptions of gelatinase A,
matrilysin, MMP-19 and epilysin, which are constitutively expressed in normal tissues, most
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MMPs  are  induced  only  in  repair  or  remodeling  processes  or  in  response  to  disease  or
inflammation (Ra and Parks, 2007). Several of the Mmp promoters, however, share common
elements. The promoters of the Mmp -1, -3, -7, -9, -10, -12, -13, -19, and -26 genes all contain
a TATA-box approximately 30 bp prior to their transcription start sites and an activating
protein -1 (AP-1) binding site at approximately -70 bp (Yan and Boyd, 2007). Cytokines and
growth factors including interferons, interleukins, epidermal growth factor (EGF),
keratinocyte growth factor (KGF), nerve growth factor (NGF), basic FGF, VEGF, platelet-
derived growth factor (PDGF), TNF-a and TGF-b can induce the proto-oncogenes c-fos and
c-jun. The proteins encoded by these genes heterodimerize and bind to the AP-1 sites, thus
regulating the activity of these Mmp genes. In addition, these promoters often contain a PEA-
3 (phosphoprotein enriched in astrocytes) site, which binds the ETS (E26 transformation-
specific) family of oncoproteins, and cooperates with the AP-1 site in regulating the genes.
The  close  proximity  of  these  two  regulatory  sites  within  the  promoters  is  crucial  for  the
interaction. As many MMPs release active growth factors from the ECM, negative and
positive feedback loops are created where the MMPs eventually regulate their own expression
(Sternlicht and Werb, 2001). Coordination of the basal expression of Mmp genes based on
similarities  in  their  promoter  structures  has  also  been  proposed,  for  example  in  the  case  of
gelatinase A and MT1-MMP, and also their inhibitor TIMP-2 (Lohi et al., 2000). The
promoters of these genes all include a functional binding site for the transcriptional activator
Sp1 (specificity protein 1).This is consistent with the coordinated function of these proteins in
the activation of gelatinase A.
Numerous other regulatory elements have been implicated within different Mmp
promoters, for example TGF-b inhibitory sites, AP-2, Sp3, nuclear factor kB (NF-kB) and
retinoic acid response elements that are found in several Mmp promoters (Sternlicht and
Werb,  2001).  The  effect  of  specific  growth  factors  can,  however,  be  divergent  on  different
Mmp genes (Folgueras et  al., 2004). TGF-b,  for  example,  suppresses  the  expression  of
collagenase-1 and stromelysin-1 but induces the expression of collagenase-3 (Uria et al.,
1998) and stromelysin-2 (Wilkins-Port and Higgins, 2007). The effects can also be cell type
specific as for example phorbol esters preferentially induce the expression of stromelysin-1 in
fibroblasts but of stromelysin-2 in keratinocytes (Windsor et al., 1993).
Promoter polymorphisms that affect gene regulation have been identified in some Mmp
genes (Ye, 2000). For example, single-nucleotide polymorphisms (SNPs) within the
stromelysin-1, gelatinase B and metalloelastase promoters have been described to increase the
susceptibility to coronary artery disease. Further, a SNP in the collagenase-1 promoter has
been associated with increased promoter activity and increased susceptibility to lung cancer.
Conversely, a SNP in the stromelysin-1 promoter has been associated with decreased
promoter activity and decreased susceptibility to lung cancer (Yan and Boyd, 2007).
Recently, the epigenetic regulation of Mmp gene expression has been carefully investigated
and there is now evidence for the contribution of both methylation and histone acetylation in
the regulation of Mmp gene expression (Clark et al., 2007). Post-transcriptional regulation,
mainly regulation of mRNA stability, has also been observed (Yan and Boyd, 2007).
1.2.4.2 Activation of latent MMPs
All MMPs are translated as inactive precursors, and activation of the latent enzymes by
removal of the prodomain is another important point of regulation of their catalytic activity.
This can be achieved by numerous mechanisms in vitro, but only a few relevant in vivo
processes activating specific MMPs have been described (Ra and Parks, 2007). All MT-
MMPs, stromelysin-3 and epilysin, contain an RXKR sequence at the C-terminal end of their
prodomains that serves as a target for the furin-family of proprotein convertases (Bassi et al.,
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2005). These MMPs are thus intracellularly activated by proteolytic removal of their
prodomains during the secretory pathway.
The activation of other MMPs is achieved through proteolytic processing by other
proteases. Several MMPs can activate other MMPs in vitro by cleaving their prodomains
(Table I). The relevance of this mode of activation in vivo is  not,  however,  certain  as
coexpression of activating MMPs and their potential MMP substrates in tissues and
colocalization in the pericellular space in many cases are not evident. For example,
stromelysin-1 efficiently activates procollagenase-1 and promatrilysin in vitro, but in vivo
these proteases are not typically coexpressed (Ra and Parks, 2007).
The  best  described  example  of  an  MMP  activating  another  MMP  is  the  activation  of
gelatinase A on the cell surface by MT1-MMP. This activation is achieved through an
intricate mechanism including the formation of a complex of gelatinase A, MT1-MMP and
TIMP-2 (Strongin et al., 1995). This process is dependent on homo-oligomerization of MT1-
MMP molecules through interactions between the hemopexin and cytoplasmic domains of
adjacent molecules (Itoh et  al., 2001; Lehti et al., 2002). Plasmin and other serine proteases
have also been implicated in the activation of proMMPs (Monea et al., 2002; Ra and Parks,
2007). Pro-MMPs can further be subjected to so called allosteric activation. This is achieved
through interactions between pro-MMPs and other molecules that induce a conformational
change in the pro-MMP disrupting the cysteine-zinc interaction and allowing autolytic
cleavage of the prodomain. Oxidants generated by leukocytes and other cell types are an
example of molecules that can both activate and inactivate MMPs by modifying critical
amino acids via oxidation. Several proMMPs are activated in vitro by reactive oxygen species
(ROS) but their role has not been confirmed in vivo (Fu et al., 2007).
In all situations, however, the removal of the prodomain does not seem to be obligatory
for MMP activation as long as the interaction between the conserved cysteine residue in the
prodomain and the active site zinc ion is disrupted (Fu et al., 2007). In epidermal wound
healing, for example, the catalytic activity of collagenase-1 is required for keratinocyte
migration on type I collagen (Pilcher et al.,  1997)  but  in  tissues  only  the  pro-form  of  this
enzyme has been detected (Dumin et al., 2001). In this setting procollagenase-1 binds to the
a2b1 integrin, which functions as a collagen receptor. The a2b1 integrin possibly induces an
active conformation of procollagenase-1 without the removal of the prodomain and only in
the presence of collagen I. Thus, a2b1 integrin would serve to target collagenase-1 to the basal
surface of keratinocytes and induce its activity transiently when in contact with its preferred
substrate (Fu et al., 2007).
It has also been questioned whether  removal of the prodomain of MT1-MMP is needed
for its catalytic activity (Cao et al., 1996; 1998). Its prodomain has instead been suggested to
serve as a chaperone regulating the folding and trafficking of the enzyme (Cao et al., 2000), a
function dependent on a conserved YGYL sequence (Pavlaki et al., 2002). This sequence is
found in the prodomains of all MT-MMPs but among the secreted MMPs only in MMPs 19
(Cossins et al., 1996; Pendas et al., 1997) and 28 (Lohi et al., 2001).
1.2.4.3 Pericellular localization
Compartmentalization is an important aspect in the regulation of MMP activity. MMPs are
not randomly released to the extracellular compartment but instead there are specific
mechanisms that confine and concentrate proteinases in the immediate pericellular
environment, targeting their catalytic activity to specific substrates in this location (Ra and
Parks, 2007). In biological situations the high ratio of proteinase inhibitors to active
proteinases protects the tissues from degradation. Therefore the ability to generate focused
proteolytic activity in the pericellular space is crucial to locally overcome the molar excess of
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inhibitors and allow for cell movement (Sternlicht and Werb, 2001). Integration of the MT-
MMPs into the cell membrane is crucial for their ability to promote cell invasion (Hotary et
al., 2000) and several of the soluble MMPs are also confined to the pericellular environment
through interactions with specific cell surface receptors (Fig. 5). For example, gelatinase A
binds to the avb3 integrin (Brooks et al., 1996), gelatinase B to CD44 (Yu and Stamenkovic,
1999) and collagenase-1 to the a2b1 integrin (Dumin et al., 2001; Stricker et al., 2001).
Matrilysin in turn, binds to heparan sulfate (Yu and Woessner, 2000; Yu et al., 2002),
cholesterol (Yamamoto et al., 2006) and the tetraspanin CD151 (Shiomi et al., 2005). Of
these cell surface molecules, at least CD44 and a2b1 integrin have also been proposed to
mediate MMP activation and to interact with specific substrate molecules, hence greatly
favoring proteolysis. TIMP-2 can simultaneously bind to the hemopexin domain of
progelatinase A and the catalytic domain of MT1-MMP. Progelatinase A can be activated in
this complex by another, adjacent MT1-MMP molecule, thus both sequestering gelatinase A
to the cell surface and inducing its catalytic activity in this location.
Figure 5. Localization of MMPs at the cell surface: The MT-MMPs are attached to the cell surface by single
transmembrane and cytoplasmic domains (1), or by GPI-anchors (2). Soluble MMPs bind to cell surface
molecules such as CD44, heparan sulfates (3) or integrins (4). Gelatinase A binds to MT1-MMP on the cell
surface through TIMP-2 (5).
In contrast to the general perception of MMPs, an alternatively spliced form of
stromelysin-3 can be translated as an active, intracellular proteinase (Luo et al., 2002). Other
MMPs with reported intracellular functions are collagenase-1, which associates with
mitochondria and confers resistance to apoptosis (Limb et al., 2005) and gelatinase A, which
digests troponin I contributing to myocardial dysfunction upon ischemia (Wang et al., 2002).
Further, MMP-26 degrades the intracellular part of the estrogen receptor b delaying cancer
progression in hormone sensitive breast carcinomas (Savinov et al., 2006) whereas MT1-
MMP can promote chromatin instability by degrading the centrosomal protein pericentrin
(Golubkov et al., 2005). Mislocalization of MT1-MMP in cancer thus contributes to
pathogenesis by allowing interactions between this proteases and normally unavailable
intracellular substrates, which further emphasizes the importance of proper
compartmentalization (Strongin, 2006).
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1.2.4.4 Inhibition of MMP activity
The catalytic activity of MMPs is also regulated by endogenous inhibitors. The major
inhibitor in tissue fluids is the abundant plasma protein a2-macroglobulin, which forms
complexes with MMPs that then bind to scavenger receptors and are irreversibly cleared by
endocytosis. Thrombospondins function similarly in complex with certain MMPs (Egeblad
and Werb, 2002).
The tissue inhibitors of MMPs (TIMPs) are secreted proteins that specifically and
reversibly inhibit MMPs (Lambert et al., 2004). In contrast to a2-macroglobulin, the four
TIMPs act more locally and their tissue expression and affinity towards individual MMPs
differ. The balance between MMPs and TIMPs is an important factor regulating ECM
turnover and remodeling in healthy tissues, and disruption of this balance has been implicated
in processes like angiogenesis and cancer invasion. In addition, TIMPs have biological effects
on cell growth and survival that cannot always be explained by their ability to inhibit MMP
activity  (Table  II).  TIMP-1  was  first  identified  as  an  erythroid  potentiating  agent,  a  feature
shared  by  TIMP-2.  TIMP-1  can  confer  resistance  to  apoptosis  whereas  TIMPs  2  and  3
promote cell death (Lambert et al., 2004). The TIMPs further affect cell signaling through
interactions with cell surface receptors such as a3b1 and VEGF receptor-2 (Chirco et al.,
2006).
The membrane anchored glycoprotein RECK (reversion-inducing cysteine-rich protein
with Kazal motifs) is a different type of MMP inhibitor. It inhibits the catalytic activity of at
least gelatinases A and B and MT1-MMP, and is a potent inhibitor of tumor invasion and
metastasis (Oh et al., 2001). RECK is expressed in most human tissues and nonmalignant
cells, whereas its expression is repressed in most cancer cells (Takahashi et al., 1998). RECK
has probably other functions aside from blocking MMP activity as disruption of the gene in
mice is embryonic lethal (Oh et al., 2001).
1.2.5 Modulation of bioactive molecules by MMPs
MMPs can degrade most components of the ECM, at least in vitro (Table I). The biological
actions of individual MMPs are, however, much more restricted as the expression and
activation  of  MMPs  are  strictly  regulated  in  both  time  and  space  (Parks et  al., 2004). The
identification of in vivo substrates for MMPs contributes critically to the understanding of
their functions in both development and disease. Technologies applied to identify the
biological functions of MMPs include the generation of genetically modified mice where
specific MMPs are either overexpressed or abrogated (Table II, Overall and Blobel, 2007). An
emerging view of MMP biology is that matrix degradation is not their sole function, as they
react to challenges like injury, inflammation or cancer by releasing specific signaling
molecules, such as cryptic fragments of ECM molecules with biological functions, growth
factors and cell-adhesion molecules in the pericellular microenvironment (Parks et al., 2004).
1.2.5.1 Cryptic fragments of ECM molecules
Cleavage of ECM molecules by MMPs frequently generates fragments that display biological
functions different from their precursors or reveal biologically relevant cryptic epitopes
within ECM molecules. For example, both gelatinases A and B can promote angiogenesis by
exposing a cryptic epitope within collagen IV, but MMPs also release fragments of ECM
molecules that are anti-angiogenic (Mott and Werb, 2004). For example, gelatinase B can
release  a  fragment  from  collagen  IV  that  has  been  named  tumstatin.  Decreased  amounts  of
circulating tumstatin is accompanied by accelerated tumor growth in gelatinase B deficient
mice, emphasizing the biological relevance of this fragment (Hamano et  al., 2003).
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Angiostatin is an anti-angiogenic fragment that is cleaved from plasminogen by
metalloelastase (Dong et al., 1997; Cornelius et al. 1998), matrilysin and gelatinase B in vivo
(Pozzi et al., 2000). Further, the cleavage of the laiminin-5 g2 chain by MMPs releases a
fragment that induces epithelial cell migration. Mice deficient in MT1-MMP have reduced
amounts of this fragment in their tissues indicating that this cleavage occurs in vivo and
possibly affects epithelial tissue organization (Koshikawa et al., 2004).
1.2.5.2 Growth factors and cytokines
The ECM functions as a reservoir for latent growth factors like TGF-b and VEGF that can be
released and activated by proteolysis. In the ECM the mature form of the multifunctional
TGF-b is associated noncovalently with its propeptide (latency-associated peptide, LAP) and
to LTPB (Saharinen et al., 1999; Hyytiäinen et al., 2004). A pool of inactive TGF-b is hence
maintained in the ECM from where the mature molecule can be activated when needed.
Several MMPs directly activate TGF-b via  cleavage  of  the  LAP  complex in vitro (Yu and
Stamenkovic, 2000; D'Angelo et al., 2001; Karsdal et al., 2002), but in vivo this function has
been associated only with MT1-MMP (Mu et al., 2002) and gelatinase A (Ge and Greenspan,
2006). VEGF is a central factor in angiogenesis that stimulates the growth of new vessels. It
binds heparan sulfate proteoglycans in the ECM. Gelatinase B has been implicated in the
release  of  VEGF from the  ECM in  different  tumor  models,  where  angiogenesis  is  a  crucial
factor regulating tumor growth (Mott and Werb, 2004). MT1-MMP likewise upregulates the
expression of VEGF in tumor cells (Deryugina et al., 2002). MMPs have also been implicated
in the cleavage of IGFBPs and perlecan leading to the release of IGFs and FGFs, respectively.
MMPs also act on growth factor receptors, for example by releasing the extracellular
domains of these receptors into the ECM, where they may sequester growth factors and
interfere with their binding to cell surface attached receptors (Vu and Werb, 2000). Further,
MT1-MMP associates with the PDGF receptor b on the membrane of vascular smooth muscle
cells promoting PDGF-B-induced signaling via the receptor. Through this complex MT1-
MMP can affect vessel wall architecture in vivo (Lehti et al., 2005).
Chemokines are chemotactic molecules that attract cells of the immune system to sites
of injury or infection. MMPs have been implicated in the regulation of chemokine activity
through direct cleavage of these molecules, thus enhancing, repressing or antagonizing their
activities. MMPs can thus be both pro and anti-inflammatory agents (Page-McCaw et al.,
2007). The effects of MMPs on chemokines can also be indirect as they modulate other
proteins that bind the chemokines to concentrate them in specific locations. In this way the
MMPs are involved in the generation of chemokine gradients guiding migrating leukocytes to
target sites (Parks et al., 2004; Manicone and McGuire, 2007).
1.2.5.3 Cell adhesion molecules
Cell adhesion molecules are also important MMP substrates involved in numerous biological
processes. E-cadherin is a transmembrane cell-cell adhesion glycoprotein localized at
adherence junctions between epithelial cells. It contains a cytoplasmic tail by which it is
connected to the actin microfilaments of the cytoskeleton via b- and a-catenin. E-cadherin is
cleaved by stromelysin-1 and matrilysin in cultured epithelial cells (Noë et al., 2001) and by
gelatinase B in ovarian cancer cells (Symowicz et al., 2007) This cleavage results in the
release of a soluble E-cadherin fragment that functions in a paracrine fashion inhibiting E-
cadherin mediated cell aggregation. This fragment further induces invasion via the
upregulation of gelatinases A and B and MT1-MMP (Nawrocki-Raby et al., 2003). Further,
MT1-MMP can mediate the shedding of both E- and N-cadherins in a kidney ischemia model
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(Covington et al., 2006). Matrilysin mediates the shedding of E-cadherin from injured lung
epithelium in vivo, and matrilysin deficient mice show decreased epithelial cell migration
after injury (McGuire et al., 2003).
The cell adhesion molecule CD44 is a cell surface glycoprotein involved in numerous
ways in cell-cell and cell-ECM interactions, which also functions as a cell surface receptor for
gelatinase B. CD44 is shed by MT1-MMP, leading to increased cell migration (Kajita et al.,
2001). Another cell adhesion molecule that is cleaved by MMPs is syndecan-1, which is an
abundant cell surface heparan sulfate proteoglycan on epithelial cells, mediating interactions
between cells and several ECM molecules. Cleavage of syndecan-1 by MT1-MMP stimulates
cell migration (Endo et al., 2003). Further, matrilysin mediates shedding of syndecan-1 in
complex with the keratinocyte-derived chemokine KC (also known as CXCL1 in the mouse
and as GROa in humans) from the mucosa of injured lungs in vivo. This process is necessary
for directing neutrophil influx to the site of injury (Li et al., 2002). MT1-MMP also interacts
with and cleaves the intracellular adhesion molecule-1 (ICAM-1), thus favoring
transmigration of leukocytes through the endothelial cell layer (Sithu et al., 2007).
1.3 Epithelial to mesenchymal transition
Epithelial cells form uniform layers where regularly spaced cell-cell junctions and adhesion
between neighboring cells hold them tightly together and restrain the movement of individual
cells away from the layer. Epithelial cell layers surround organs and line cavities in the
organism providing them with structural support and serving as a surface for interactions
between the underlying stromal tissue and the outside. The epithelial cell layer is polarized.
The basal and apical surfaces express different surface molecules and serve different
functions. Mesenchymal cells, in contrast, form irregular structures with weak intracellular
adhesion, which facilitates migration. Mesenchymal cells have a more elongated shape and
are able to move individually, whereas epithelial cells in general move as a sheet (Lee et al.,
2006).
Epithelial to mesenchymal transition (EMT) is a fundamental biological process where
epithelial cells acquire a more mesenchymal phenotype, including the loss of polarity and the
adoption of a morphology appropriate for migration and invasion. Hallmarks of EMT are loss
of cell-cell adhesion receptors, loss of cell-matrix contacts and changes in the composition of
the intermediate filament cytoskeleton. EMT is a critical process in the induction of cell
movement and provides stationary cells with the means to invade into surrounding tissues.
EMT is therefore essential in embryonic development, but it can also be induced in adult
tissues, which contributes to the development and progression of pathological processes such
as fibrosis and cancer (Thiery, 2002; Huber et al., 2005). EMT can be induced through
different molecular pathways by combining the actions of locally expressed growth factors
with proteolytic degradation of critical targets. These targets comprise the BMs on which the
epithelial cells reside and adhesion molecules holding the epithelial sheet intact (Kalluri and
Neilson, 2003). Degradation of E-cadherin is a crucial event involved in EMT, invasive tumor
growth and metastasis (Bissell and Radisky, 2001; Tse and Kalluri, 2007). As noted above
(section 1.2.5.3) several MMPs are able to cleave the extracellular part of E-cadherin, and as a
result of this contribute to the induction and progression of EMT. MMPs are, however, also
involved in several other molecular pathways, which contribute to the transformation of
epithelial cells (Fig. 6, Egeblad and Werb, 2002; Page-McCaw et  al., 2007; Przybylo and
Radisky 2007).
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Figure 6: MMPs affect EMT. MMPs can contribute to EMT by different actions. MMPs release and activate
ECM-bound latent TGF-b (1). TGF-b is  a  potent  inducer  of  EMT,  and  its  main  target  in  this  process  is  the
transcriptional regulator Snail (2). Snail downregulates the expression of the cell surface adhesion receptor E-
cadherin (3), the loss of which is an important event in the induction of EMT. Snail also induces the expression
of certain Mmp genes (4). MMPs may further induce EMT through the shedding of the extracellular part of E-
cadherin  (5).  MMPs also  release  other  growth  factors  from the  ECM that  facilitate  the  induction  of  EMT and
also regulate the expression of the MMPs themselves (6). Some MMPs participate in the degradation of the BM
(7), another action contributing to EMT.  Stromelysin-1 (MMP-3) can induce EMT through the degradation of
E-cadherin (3), but also through the induction of Snail via Rac1b and the release of intracellular ROS (8).
1.3.1 Role of MMPs in growth factor mediated EMT
Induction of EMT is facilitated by local expression of TGF-b, EGF, IGF-II or FGF-2 (Thiery,
2002),  all  of  which  can  be  released  from  the  ECM  through  the  actions  of  MMPs  (Vu  and
Werb,  2000).  The  ability  of  TGF-b to inhibit the growth of normal cells is well known
(Massague  and  Gomis,  2006).  Nevertheless,  members  of  the  TGF-b family can induce and
maintain EMT in a variety of biological and pathological processes like cancer and fibrosis
(Miettinen et al., 1994; Zavadil and Böttinger, 2005). TGF-b thus plays a dual role in cancer
as it promotes the acquisition of an invasive phenotype in tumor cells that have become
resistant to its growth inhibitory effects (Moustakas et al., 2002). Little is known of the
complex events underlying the conversion of TGF-b from a growth inhibiting to a tumor
promoting growth factor. It is possible, that a change in the repertoire of available
intracellular signal mediators shifts the TGF-b response from favoring growth inhibition to
promoting EMT as cancer progresses (Tse and Kalluri, 2007).
EMT can be initiated by autocrine and paracrine TGF-b activation of major signaling
pathways fundamentally altering the transcriptional activity of epithelial cells (Zavadil et al.,
2001). TGF-b activates several signaling pathways including the Smad-, Ras-, mitogen-
activated protein kinase- (MAPK), WNT-, NF-kB- and phosphatidylinositol 3 kinase- (PI3K)
pathways. Of these the Smad pathway seems to control a majority of TGF-b target genes
during EMT (Valcourt et al., 2005). Smad-3 plays a crucial role in several in vivo models of
EMT (Roberts et al., 2006), whereas Smad-2 has been pointed out as a critical mediator of
TGF-b-induced EMT in cancer progression (discussed in Lee et  al., 2006). Other signaling
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molecules and pathways, or in many cases cross-talk between different pathways, seem to
play key roles in other tissues and under different circumstances (Huber et al., 2005). The role
and effects of TGF-b in EMT is therefore highly dependent on the cellular context (Zavadil
and Böttinger, 2005; Peinado et al., 2007).
TGF-b, as well as FGF-2, further contribute to the induction of EMT by increasing the
synthesis and activation of gelatinases A and B (Strutz et  al., 2002; Li et al., 2003b; Van
Themsche et al., 2007). This has been proposed to lead to degradation of the collagen IV
component of the BM, a central process in increasing epithelial cell plasticity. Degradation of
collagen IV by gelatinase A was pointed out as an important event the TGF-b-induced EMT
in avian heart development (Song et al., 2000). However, the expression of MT1-MMP was
also increased in this study. This is an important notion as MT1-, MT2-, and MT3-MMP have
been proposed as the only proteases involved in BM degradation in vivo (Hotary et al., 2006).
Other observations support a role for gelatinase A only in the migratory phase in EMT in the
avian embryo (Duong and Erickson, 2004). In addition to the gelatinases, also collagenase-3
and MT1-MMP are frequently upregulated in EMT to drive the invasion of the phenotypically
altered cells through BMs and into surrounding tissues (Murphy and Gavrilovic, 1999; Seiki
and Yana, 2003), further emphasizing the role of MMPs in carcinogenesis. Conversely, these
MMPs can activate TGF-b in  osteoblasts,  chondrocytes,  and  epithelial  cells  (Yu  and
Stamenkovic, 2000; D'Angelo et al., 2001; Karsdal et al., 2002; Mu et al., 2002). In SCC cells
TGF-b induces the expression of collagenases 1 and 3 and enhances cell invasion via Smad
signaling (Johansson et al., 2000; Leivonen et al., 2006). In other circumstances, TGF-b
downregulates collagenase-1 and stromelysin-1 (Uria et al., 1998), pointing out the complex
relationship between TGF-b and MMP function in the induction and progression of EMT and
cancer (Derynck et al., 2001).
1.3.2 MMPs are induced by Snail and Sip1
A major target for TGF-b in EMT is the transcription factor Snail that is induced through the
MAPK, PI3K and Smad pathways (Peinado et al., 2003, Huber et al., 2005). Snail is a strong
repressor of E-cadherin expression (Batlle et al., 2000; Cano et al., 2000), and hence a potent
inducer of EMT. TGF-b can coordinate the expression and function of Snail with respect to
other transcriptional repressors, such as members of the ZEB and basic helix-loop-helix
(bHLH) families that are involved in the induction of EMT and the maintenance of the
migratory phenotype (Peinado et al., 2007). In addition to E-cadherin, Snail acts on numerous
other target molecules including the repression of other proteins involved in cell adhesion,
such as claudin and occludin (De Craene et al., 2005). In parallel, Snail induces the
production of mesenchymal marker molecules such as vimentin and fibronectin that facilitate
the movement of the transformed epithelial cells, and also of ECM remodeling enzymes, such
as the MMPs (Fig. 6). In vitro Snail has been proposed to induce the expression of gelatinase
A, matrilysin and MT1-MMP (Yokoyama et al., 2003; Miyoshi et al., 2004), but the
interactions  between  Snail  and  the  promoters  of  these  genes  are  not  understood  in  detail  at
present. When overexpressed in Madin-Darby canine kidney (MDCK) cells, Snail induces
expression  of  gelatinase  B  as  part  of  the  EMT  process  (Jorda et al., 2005). Snail does not
seem to interact directly with the gelatinase B promoter, but the binding of Sp1 to a specific
GC-box within the promoter is required for induction. Conversely, silencing of Snail by RNA
interference in carcinoma cells decreased the levels of gelatinase B and angiogenic markers,
dramatically reducing in vivo tumor growth and invasion (Olmeda et al., 2007).
Sip1 (Smad-interacting protein-1) is another transcriptional repressor of E-cadherin
(Comijn et al., 2001) which is activated in mouse mammary epithelial cells undergoing EMT
in response to TGF-b (Thiery, 2002). Sip1 can affect gene regulation either independently or
34
in concert with Snail, which possibly regulates the expression of Sip1 itself (Takkunen et al.,
2006). The Snail and Sip1 binding sites within the E-cadherin promoter are overlapping, and
these two factors are often coexpressed in carcinomas negative for E-cadherin. In vitro, Sip1
can induce the expression of collagenase-1, gelatinase A and MT1-MMP (Miyoshi et al.,
2004), but the relevance of this induction in vivo remains  unclear.  Increased  expression  of
both Sip1 and Snail has, however, been observed in several human cancers (Peinado et al.,
2007) like breast and ovarian carcinomas, where high levels of Sip1 has been correlated with
poor prognosis (Elloul et al., 2005).
A third important transcription factor repressing the E-cadherin gene and inducing
EMT is Twist, a protein known to be essential during development (Yang et al., 2006). Twist
is upregulated early during metastatic progression and has functionally been validated as a
critical regulator of lung metastasis is mammary tumor models (Yang et al., 2004).
1.3.3 MMPs induce Snail
Overexpression of stromelysin-1 in mammary epithelial cells can cause stable EMT,
accompanied by the cleavage of E-cadherin, upregulation of endogenous MMPs and
increased invasiveness (Lochter et  al., 1997). Further, when these stromelysin-1
overexpressing cells were injected into mice, they formed invasive tumors, indicating that
stromelysin-1 can trigger EMT and render cells tumorigenic and invasive also in vivo
(Sternlicht et al., 1999). Both in vivo and in vitro, stromelysin-1 activity was needed only for
the induction of EMT but not for sustaining the converted phenotype. The stromelysin-1-
induced EMT is mediated by Rac1b, an alternatively spliced form of the small GTPase Rac1,
which increases the levels of intracellular ROS, leading in turn to increased expression of
Snail and EMT (Fig. 6, Radisky et al., 2005).
In conclusion, MMPs play multiple roles in the process of EMT, both as inducers and
effectors of epithelial transformation, participating in several central regulatory pathways and
molecular feedback circuits.
1.4 MMPs in cancer
The functions of MMPs in cancer are not restricted to their role in the induction and
maintenance of the transformed epithelial phenotype. The expression and activation of MMPs
is increased in almost all human cancers where they regulate central processes like cancer cell
growth, differentiation, apoptosis, migration and invasion, and regulation of tumor
angiogenesis and function of the immune system. Increased expression of MMPs often
correlates with poor prognosis (Folgueras et al., 2004). Some MMPs, such as matrilysin, are
generally produced by cancer cells themselves, whereas others such as the gelatinases are
produced by tumor stromal cells, namely fibroblasts, inflammatory cells and endothelial cells.
MMPs exert their effects on cancer progression by cleaving a wide set of target proteins,
including both structural ECM components and also growth factor binding proteins, their
receptors and precursors, cell adhesion molecules and cell surface receptors (Westermarck
and Kähäri, 1999; Egeblad and Werb, 2002). Much of the evidence for the active role of
MMPs in cancer stems from animal studies, either concerning the growth of transplanted
MMP or TIMP-expressing cancer cells in mice, or from studies of cancer induction and
progression in genetically modified mice lacking or overexpressing specific MMPs or TIMPs
(Table II; Egeblad and Werb, 2002).
Because of the fundamental role of MMPs in cancer, the possibility to use MMP
inhibitors in anti-cancer therapy has been much investigated. Attempts have been made to
inhibit MMP synthesis, to inhibit interactions between MMPs and other proteins, to exploit
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the increased MMP activity to generate targeted toxin release and to block MMP activity
(Egeblad and Werb, 2002). The results have, however, been discouraging and none of the
developed drugs have so far passed clinical trials (Fingleton, 2007). Broad-spectrum
inhibitors have caused adverse and unforeseen side effects, revealing the critical need for
inhibitors specifically targeting individual cells and MMPs. Thorough investigations on the
biological functions of the MMPs, the redundancy and cross-talk between different family
members, and different aspects of regulating their activity are still needed (Overall and
Kleifeld, 2006; Fingleton, 2007). There is an increasing amount of evidence suggesting that
the expression of certain MMPs provides beneficial and protective effects in several stages of
cancer progression. This is an additional aspect that should be taken into consideration when
designing MMP inhibitors for clinical use (Martin and Matrisian, 2007). These observations
may also partly explain the failure of many current MMP inhibitors in clinical trials.
1.5 MMPs and other proteolytic pathways
In addition to the MMPs there are several other important protease families participating in
the remodeling of the ECM. These different protease systems frequently interact on the cell
surface, generating proteolytic cascades accurately fine-tuning cell signaling and phenotype
according to the conditions of the cellular microenvironment (Sternlicht and Werb, 2001).
ADAMs (a disintegrin-like and metalloproteinase domain) are transmembrane cell surface
metalloproteinases that are involved in the shedding of the extracellular domains of several
membrane-bound proteins. ADAMs activate several growth factors and cytokines and
regulate signaling pathways involved in various processes from development to cancer
progression (Huovila et  al., 2005). For example ADAM-17 (TNF-a converting enzyme,
TACE) cleaves and activates membrane-bound TNF-a in vivo (Peschon et  al., 1998). The
ADAMs also contain a disintegrin-like domain through which individual family members can
participate in cell adhesion via interactions with integrins. The ADAMTS (ADAM with
trombospondin motifs) metalloproteinases are secreted enzymes that contain at least one
trombospondin type I repeat. They are involved in the processing of procollagens and other
ECM proteins such as aggrecan, and play important roles in processes like ECM organization,
inflammation and cell migration (Apte, 2004). The activity of the ADAMs is regulated by the
TIMPs, and like MMPs, the affinity of specific TIMPs for specific ADAMs is individual.
Only TIMP-3 can inhibit the ADAMTS proteases (Kashiwagi et al., 2001).
 Serine proteases, such as the members of the plasmin activation system, are also
important mediators of pericellular proteolysis and ECM remodeling. Plasmin is primarily
involved in the proteolysis of the fibrin clot in wound healing, but can also degrade various
other ECM components. The involvement of the urokinase-type plasminogen activator (uPA)
in cell migration, invasion and tissue remodeling is enabled by its specific targeting to cell
membranes through interactions with the uPA receptor (uPAR) (Qiu et  al., 2007). Through
the activation of plasminogen, and also due to its intrinsic catalytic activity, uPA can degrade
various ECM components and activate growth factors, such as hepatocyte growth factor
(HGF)  and  TGF-b (Rifkin et al., 1999). Importantly, uPA and plasmin are also involved in
the activation of other proteases in vivo, such as collagenase-2, stromelysin-1 and gelatinase B
(Andreasen et al., 2000). In this way, proteolytic activity can be amplified at the cell surface
to locally overcome the otherwise excess of inhibitors in tissues facilitating cell movement
and ECM remodeling.
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2 Outline of the present study
When this study was initiated in 2000, epilysin had recently been cloned and initial
characterization carried out (Lohi et al., 2001). Epilysin was defined as an epithelial MMP
expressed in many human tissues unlike most other MMPs. The aim of the present work was
to elucidate the biological functions of this new MMP and to reveal its possible involvement
in pathological processes. For this purpose we generated stable cell pools overexpressing
recombinant epilysin, as the protease is expressed at low levels in cultured cells. During the
course of the study, we unexpectedly found that overexpression of epilysin causes epithelial
to mesenchymal transition in human lung carcinoma cells through mechanisms dependent on
TGF-b.
The aims of the work were:
1. to analyze how the expression of the epilysin gene is regulated through its promoter
region and to identify transcriptional regulators that interact with it. For this purpose
both the human and mouse promoters were sequenced and compared with each other
to identify conserved promoter regions potentially important in gene regulation.
2. to characterize the biochemical properties of epilysin, in particular to identify potential
substrates and other interacting proteins affecting the activation, localization and
inhibition of epilysin.
3. to clone the cDNA of the mouse epilysin homologue and compare it with the known
human cDNA.
4. to  define  the  expression  of  epilysin  in  different  tissues  in  the  mouse  and  to  explore
what physiological functions it could participate in and what kind of substrates it
could encounter in vivo.
5. to analyze how overexpression of epilysin affects the properties of cultured epithelial
cells.
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3 Materials and Methods
3.1 Cell culture and reagents
All cells were grown in Dulbecco’s modified Eagle’s medium (D-MEM) or Eagle’s minimal
essential medium (MEM) containing 10 % (v/v) heat inactivated fetal calf serum (FCS)
(Gibco BRL, Gaithersburg, MD, USA). The cell lines used are listed below along with their
American Type Culture Collection (ATCC, Manassas, VA, USA) reference number, or
reference. All cells were grown to confluency at 37?C in a humidified 5 % CO2 atmosphere.
Name: Description: Medium:
A431 human epidermoid carcinoma cells, ATCC: CRL-1555 MEM
A549 human lung adenocarcinoma cells, ATCC: CCL-185 MEM
CHO Chinese-hamster ovary epithelial cells, ATCC: CCL-61 D-MEM
GC-1 spg mouse pSV3-neo transformed spermatogonia, (Hofmann et al., 1992) MEM-
HaCaT immortalized human keratinocytes, (Boukamp et al., 1988)_ D-MEM
HT-1080 human fibrosarcoma cells, ATCC: CCL-121 MEM
MDCK canine kidney epithelial cells, ATCC: CCL-34 MEM-
3.1.1 Antibodies
Antigen: Product nr: Manufacturer or laboratories:
E-cadherin HECD-1 Zymed, San Francisco, CA, USA
Epilysin Lohi et al., 2001; polyclonal rabbit anti-human IgG
HGF AF-294-A R&D Systems
LTBP-1 Ab-39 Carl-Henrik Heldin, Ludwig Institute for Cancer Reserch, Uppsala, SWE
LTBP-4 Koli et al., 2005;  mouse monoclonal anti-human IgG
Matrilysin Carole Wilson, University of Washington, Seattle, WA, USA
MT1-MMP RP1MMP14 Triple Point Biologics, Forest Grove, OR, USA
MT1-MMP Lehti et al., 2000; polyclonal rabbit anti-human IgG
P-SMAD-2 Peter ten Dijke, The Netherlands Cancer Institute, Amsterdam, NL
Sp1 (1C6) sc-420 Santa Cruz Biotechnology, Santa Cruz, CA, USA
Sp2 (K-20) sc-643 Santa Cruz Biotechnology
Sp3 (D-20) sc-644 Santa Cruz Biotechnology
Sp4 (V-20) sc-645 Santa Cruz Biotechnology
Stromelysin-1 AB19150 Chemicon, Temecula, CA, USA
TGF-b1/LAP Taipale et al., 1994; affinity-purified rabbit anti-human IgG
TGF-b AB-100-NA R&D Systems
V5 R960-25 Invitrogen, San Diego, CA, USA
3.1.2 Enzymes, chemicals and growth factors
All restriction enzymes and ligases were from New England BioLabs (Beverly, MA, USA)
unless specified elsewhere. PCR was performed using AmpliTaq GoldTM (Applied
Biosystems, Foster City, CA, USA) and RT-PCR using Superscript II RT (Gibco) according
to manufacturers’ instructions. Recombinant TGF-b and  HGF  were  from  R&D  Systems
(Minneapolis, MN, USA). The synthetic MMP inhibitors BB-3103 and GM6001 were from
British Biotech Pharmaceuticals Ltd (Oxford,  UK) and Calbiochem (San Diego, CA, USA),
respectively. Other chemicals used were Decanoyl-Arg-Val-Lys-Arg-chloromethylketone
(CMK) (Bachem, Bubendorf, Switzerland), N-glycosidase F (Roche, Mannheim, Germany)
and puromycin (Sigma Chemical Co., St Louis, MO, USA).
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3.2 DNA and protein/DNA interaction analysis
3.2.1 Construction of expression vectors
The sequences of expression vectors generated in this work are outlined below, as well as
commercial vectors applied. SS denotes signal sequence, PRO denotes prodomain, CAT
denotes catalytic domain and PEX denotes hemopexin domain. Mutations in the sequence are
denoted by an X.
Name: Vector: Insert: Tag:
Human epilysin promoter
pro3031bp pGL3-Basic -3031¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ +1 LUC
pro1486bp pGL3-Basic -1486 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ +1 LUC
pro1167bp pGL3-Basic -1167 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ +1 LUC
pro653bp pGL3-Basic -653 ¾¾¾¾¾¾¾¾¾¾¾ +1 LUC
pro533bp pGL3-Basic -533 ¾¾¾¾¾¾¾¾¾ +1 LUC
pro489bp pGL3-Basic -489 ¾¾¾¾¾¾¾+1 LUC
pro439bp pGL3-Basic -439 ¾¾¾¾¾+1 LUC
pro402bp pGL3-Basic -402 ¾¾¾¾ +1 LUC
pro344bp pGL3-Basic -344 ¾¾¾ +1 LUC
pro298bp pGL3-Basic -298 ¾¾ +1 LUC
pro274bp pGL3-Basic -274 ¾ +1 LUC
pro1486bpREV pGL3-Basic +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ -1486 LUC
pro653bpMUT pGL3-Basic -653 ¾X¾¾¾¾¾¾¾¾¾ +1 LUC
pro344MUT pGL3-Basic -344 X¾¾ +1 LUC
Mouse epilysin promoter
mpro657bp pGL3-Basic -657 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ +1 LUC
mpro162bp pGL3-Basic -162 ¾¾¾¾ +1 LUC
mpro657bpREV pGL3-Basic +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾ -657 LUC
Mouse epilysin cDNA
+1     SS   I      PRO     I         CAT       I            PEX       +1560
mEpiS pcDNA3 +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾  +1560
mEpiM pcDNA3 +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ /           /¾¾¾ +1560
mEpiL pcDNA3 +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ /               /¾¾ +1560
pEF-mEpi pEF-IRESp +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾  +1560
Human epilysin cDNA
+1     SS   I      PRO     I         CAT       I            PEX       +1560
Epi pEF-IRESp +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾  +1560
Epi-E/A pEF-IRESp +1 ¾¾¾ E241A ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ +1560
Epi* pEF1/V5-His +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾  +1560 V5
Epi-E/A* pEF1/V5-His +1 ¾¾¾ E241A ¾¾¾¾¾¾¾¾¾¾¾¾¾¾¾ +1560 V5
Cat* pEF1/V5-His +1 ¾¾¾¾¾¾¾¾¾¾¾¾¾  +852 .. ..................... V5
Pex* pEF1/V5-His +1 ¾¾ +66 ................  .     .+853 ¾¾¾¾¾¾¾ +1560 V5
Vector: Manufacturer:
pBluescriptII KS(+) Stratagene, La Jolla, CA, USA
pcDNA3 Invitrogen
pCM5-EGFP Invitrogen
pEF-IRES-P Hobbs et al., 1998
pEF1/V5-His Invitrogen
pGEM-4Z Promega, Madison, WI, USA
pGL3 Basic Promega
pRL-TK Promega
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3.2.2 Transfections
Cells were washed twice in serum free medium and kept in this media for 24 h prior to
transfections. All cells lines, except HaCaT keratinocytes, were transfected using FuGENE 6
(Roche) according to manufacturer’s instructions. HaCaT cells on 6-well plates were
transfected using 1.5 ?g of DNA diluted to 110 µl in Hank’s salt solution including 40 µg
DEAE-dextran (Promega). Before addition of the DNA-dextran mix, the cells were changed
to serum free medium containing 100 µM chloroquine (Promega). After 3 h, the cells were
subjected to a 2-min glycerol shock (15 % glycerol in Hanks’ salt solution). After transient
transfections, cells were incubated in serum free growth medium for 24 or 48 h before
analysis.
To generate cell lines with stable, high level expression of different epilysin constructs
in the pEF-IRES-P vector, cells were transferred to growth medium containing 1 mg/ml
puromycin the day after transfection. During the following 14 days the puromycin
concentration was gradually increased to 80 mg/ml (HT-1080, II) or 20 ?g/ml (A549, III),
selecting a pool of cells with high expression levels of epilysin or the empty vector.
3.2.3 Promoter activity assays
Cells transfected with reporter plasmids containing parts of the epilysin promoter attached to
the firefly luciferase gene and the pRL-TK control vector containing the Renilla luciferase
gene, were lysed in reporter lysis buffer and analyzed for firefly and Renilla luciferase
activities using the Dual-Luciferase Reporter Assay System kit (Promega). Firefly luciferase
values were normalized to the renilla value of each sample.
3.2.4 Gel mobility shift assay
For  gel  mobility  shift  assays  (GMSA)  nuclear  extracts  of  HaCaT  and  GC-1  spg  cells  were
prepared as described (Andrews and Faller, 1991). To determine the binding of nuclear
proteins to the GT-box, an oligonucleotide containing this element (5´-
GCGGGGTGGGTGGGGCGGGAG-3´)  was  labeled  with  [g-32P]ATP,  annealed  to  its
complementary strand, and used as a probe in gel mobility shift assays. Nuclear extracts (6 µg
per reaction) were incubated on ice for 20 min in a reaction buffer containing 10 mM HEPES
pH 7.9, 60 mM KCl, 1 mM EDTA, 5 mM DTT, 5 mM MgCl2, 10 µM ZnCl2, 10 % glycerol, 4
mM spermidine, 1 µg poly(dI-dC) and 35 fmol labeled probe. For competition experiments,
nuclear extracts were preincubated on ice for 30 min with a 100-fold molar excess of
unlabeled  probe  or  a  mutated  version  of  the  probe  (5´-GCGGGGTGGTTTGGGCGGGAG-
3´). Binding to the probe was also competed with a 100-fold molar excess of unlabeled
consensus Sp1-oligonucleotide (5´-ATTCGATCGGGGCGGGGCGAGC-3´, Santa Cruz
Biotechnology) before addition of the 32P-labeled probe. For supershift assays the nuclear
extracts were preincubated with 2 µg of anti human Sp1, Sp2, Sp3 or Sp4 IgG. DNA-protein
complexes  were  then  resolved  by  electrophoresis  in  a  native  4%  PAGE  in  0.5  X  TBE
containing 2.5 % glycerol.
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3.3 RNA analysis
3.3.1 Extraction of RNA from mouse tissues
Tissue samples were collected from 6-8 week-old, male, NMRI mice. Female reproductive
organs were collected from corresponding female mice, and embryos from timed pregnant
mice. The samples were frozen in liquid nitrogen. For RNA extraction, the frozen tissues
were first disrupted using a mortar and further homogenized in TRIzolÒ Reagent (Gibco)
using a syringe and a 26G needle, and RNA extraction was carried out according to
manufacturer’s instructions.
3.3.2 RNase protection analysis
Ribonuclease protection assay was used to determine the transcription start site in the human
epilysin gene (I), by hybridizing mRNA from HaCaT keratinocytes to an 689 nt [a-32P]UTP
labeled  anti-sense  RNA probe,  which  covers  bases  –653 to  +1  of  the  epilysin  promoter.  To
determine the expression of epilysin in different tissues from the mouse (II), total RNA
samples were hybridized to a 370 nt [a-32P]UTP labeled anti-sense cRNA probe covering
bases 970-1241 of the epilysin cDNA. The probes (100,000 cpm per sample) were hybridized
with 10 µg of poly-A RNA or 20 mg of total RNA, respectively. After overnight hybridization
unpaired RNA was degraded with a mixture of RNase A and RNase T1 at 37°C for 1 h,
followed  by  isopropanol  precipitation  (Direct  Protect  Kit,  Ambion  Inc.,  Austin,  TX,  USA).
Protected RNA fragments were separated by polyacrylamide gel electrophoresis in a 5 %
TBE-gel containing 6 M urea (Bio Rad, Hercules, CA, USA) and visualized by
autoradiography. An antisense cRNA probe complementary to the mouse glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA (Ambion) was used as an internal control in
comparing  the  epilysin  levels  of  different  tissues.  Epilysin-  and  GAPDH-bands  were
quantified using a phosphorimager and the epilysin content of each sample was normalized
against its GAPDH content (II).
3.3.3 Northern hybridization
A Mouse MTNâ blot with 2 mg of mRNA from different mouse tissues was purchased from
Clontech (Palo Alto, CA, USA). A 1.5 kb DNA fragment covering the entire coding area of
the epilysin mRNA was labeled using [a-32P]dATP  and  the  Strip-EZ  DNAä labeling kit
(Ambion). Hybridization was performed in Ultrahyb (Ambion) using 107 cpm/ml of labeled
probe. After extensive washing of the filter, positive bands were identified by
autoradiography (II).
3.4 Protein analysis
3.4.1 Immunofluorescence
Stable cell pools were kept in serum free media 24 h prior to immunofluorescence analysis.
Transiently transfected cells were kept for 24 (III) or 48 (II) h after transfection in serum free
media before the cells were washed in phosphate buffered saline (PBS) and fixed using 3 %
paraformaldehyde (PFA) and permeabilized with 0.1 % Triton X-100. Nonspecific binding
sites were saturated with bovine serum albumin (BSA, 5 % solution in PBS), followed by a 1
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h incubation with primary antibodies in PBS (II, III). Alternatively, the living cells on glass
coverslips were washed with cold PBS and incubated with primary antibodies on ice for 30
min prior to fixation and blocking of nonspecific binding sites (III). For indirect
immunofluorescence the cells were incubated with Alexa-conjugated secondary antibodies
(Molecular Probes, Eugene, OR, USA), and mounted using VectaShield (Vector Laboratories,
Burlingame, CA, USA) containing DAPI to stain the nuclei. Images were obtained using
fluorescence microscopy and a digital camera.
3.4.2 SDS-PAGE and immunoblotting
Confluent cell cultures were washed and incubated for 24 (III) or 48 (II) h in serum free
MEM. Transiently transfected cells were incubated for 24 h after transfection prior to
transferring to serum free medium. The conditioned media were then harvested and cell
lysates prepared as described (Lehti et al., 1998). The medium was supplemented with the
MMP inhibitor GM6001 (5 µM, final concentration) where indicated. The conditioned media
were clarified by centrifugation and concentrated 10-fold using Microcon concentrators
(Millipore, Bedford, MA, USA). Aliquots of conditioned medium and cell lysates from the
same number of cells were denatured at + 100°C for 3 min in Laemmli sample buffer
containing 10 % b-mercaptoethanol (final concentration). The polypeptides of the samples
were separated by SDS-PAGE and analyzed by immunoblotting as described (Lohi et al.,
2001), using 7.5 % standard or 4-15 % gradient polyacrylamide gels (Bio Rad) and the
SuperSignal West Dura Extended chemiluminescence kit (Pierce Chemical, Rockford, CA,
USA).
3.4.3 Gelatin zymography
For gelatin zymography the medium polypeptides were dissolved in non-reducing Laemmli
sample buffer and separated on 10 % polyacrylamide gels containing gelatin (Invitrogen). The
polypeptides were permitted to refold and the gels were stained as described (Lohi et al.,
1996).
3.4.4 TGF-b activity assays
Conditioned medium from the same number of cells was analyzed for TGF-b activity either
directly (active TGF-b) or after heat treatment (total TGF-b). Heat treatment activates latent
forms  of  TGF-b (Brown et al., 1990). Mink lung epithelial cells stably transfected with a
fragment of the PAI-1 promoter fused to the luciferase gene (TMLC) were a kind gift  from
Dr.  Daniel  B.  Rifkin  (New  York  University  School  of  Medicine,  New  York,  NY,  USA).
These cells produce luciferase activity in response to TGF-b. TGF-b standards and medium
samples were analyzed as described (Abe et al., 1994). The luciferase values were compared
to the values of a dilution series of standards containing 7.8 – 500 pg/ml of recombinant TGF-
b1. Where indicated, polyclonal antibodies neutralizing the bioactivity of TGF-b and  HGF,
respectively, were used according to the manufacturer’s instructions.
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3.5 Transwell migration assays and collagen invasion
Transwell migration assays were performed using type I collagen (0.1 mg/ml; Upstate
Biotechnology, Waltham, CA, USA) coated Falcon cell culture inserts with 8 mm pore
membranes in 24-well cell culture plates. A549 cells (105) in serum free MEM were plated in
the upper chambers and MEM supplemented with 0.5 % FCS was added to the lower
chambers. The cells were allowed to migrate for 4 h after which they were fixed and stained
(40 % methanol, 10 % acetic acid and 0.1 % Coomassie Blue in H20). Cells were removed
from the upper side of the insert, and the migrated cells at the lower side of the membrane
were counted. Transiently transfected cells were co-transfected with a construct coding for the
enhanced green fluorescent protein (pCM5-EGFP), and transfected cells only were included
in the results.
Type I collagen invasion assays were performed essentially as described (Hotary et al.,
2000). The collagen solution was neutralized with NaOH and diluted to a final concentration
of 2.2 mg/ml in MEM. Collagen gels were then cast into the upper chamber of Falcon cell
culture inserts with 8 mm pore membranes in 24-well cell culture plates and allowed to set at
+37°C for 1 h. A549 cells (106/insert) in MEM containing 10 % FCS were added on top of the
gel, and MEM containing 10 % FCS supplemented with 10 ng/ml recombinant HGF to act as
a chemoattractant was added to the lower chamber. Where indicated GM6001 (10 µM, final
concentration) was added to both chambers. The cells were grown for 8 days changing the
media every third day, after which the gels were removed from the inserts, fixed in 3 % PFA,
dehydrated and embedded into paraffin. Sections were stained with hematoxylin and eosin
(HE-staining), and the invading cells were counted and photographed under a light
microscope. Both experiments were repeated three times with similar results.
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4 Results
4.1 Characterization of human and mouse epilysin promoters (I)
To analyze the function of the epilysin promoter, fragments of human and mouse genomic
DNA containing areas 5’-upstream of the epilysin gene were isolated and sequenced.
Comparison of the mouse and human sequences revealed well conserved areas within the
promoters, some of which showed homology to known promoter motifs (Fig. 1 in I). No
typical TATA-box was, however, detected and transcription start sites in the human epilysin
gene were therefore determined by RNase protection. Analysis revealed two transcription
start sites at 230 and 210 nt from the translation initiation site (Fig. 1 and 2 in I), which is
common for genes lacking a TATA-box.
4.1.1 Identification of potential regulatory sites
The human epilysin promoter was analyzed for the presence of consensus transcription factor
binding sites using internet-based search programs. A GT-box similar to the consensus
binding site for transcription factors of the Sp-family was found about 60 bp upstream from
the transcription start sites. This motif is completely conserved between the human and mouse
genes, implying a possible functional role within the promoter (Fig. 1 in I). Further, about 540
bp upstream from the translation start site in the human promoter a consensus binding site for
transcription factors of the SRY/Sox-family was found. This sequence was not conserved in
the mouse promoter, where, however, another Sox-like sequence was found close upstream.
These  two  sites  were  chosen  for  further  analysis  as  possible  regulatory  sites  within  the
epilysin promoter.
4.1.2 Analysis of transcriptional activity
To elucidate the regulatory effects of the different areas within the epilysin promoter, reporter
constructs were generated containing various fragments of the human epilysin promoter
coupled to the firefly luciferase gene (constructs illustrated in paragraph 3.2.1). The
constructs were transfected into HaCaT keratinocytes and GC-1 spg spermatogonia, which
both express endogenous epilysin, and reporter gene transcription was monitored (Fig. 3 in I).
The two shortest constructs had negligible effect on reporter gene transcription, whereas the
shortest construct including the GT-box, increased the transcriptional activity about 5-fold in
both keratinocytes and spermatogonia. To specify whether the GT-box alone was responsible
for this induction, a mutation was introduced into it (Fig. 3 in I). The transcriptional activity
of the mutated construct was reduced to the level of the shortest constructs, implicating a
central role for the GT-box as a binding site for positive regulatory factors.
All longer constructs exhibited high reporter gene activity with some differences
between  the  two  cell  lines  (Fig.  3  in  I).  The  Sox-site  in  the  receptor  construct  marginally
increased the transcriptional activity in keratinocytes, while in spermatogonia the increase
was about 40 %. Mutation of the Sox-site gave similar results indicating a cell type specific
difference in the regulation of the human epilysin gene, where the putative Sox-site plays a
more prominent role in spermatogonia than in keratinocytes. For comparison, constructs
containing 657 bp and 162 bp of the mouse promoter sequence, respectively, were generated.
In mouse spermatogonia, the 657 bp construct containing the GT-box increased reporter gene
transcription markedly, whereas the short construct had no detectable effect on transcription.
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4.1.3 The epilysin promoter interacts with Sp1 and Sp3
As  the  GT-box  seemed  important  for  the  regulation  of  the  transcriptional  activity  of  the
epilysin gene, we next analyzed by GMSA whether any nuclear proteins are bound to this
sequence (Fig. 4 in I). The results indicated that nuclear extracts from HaCaT keratinocytes
contain proteins that specifically interact with the GT-box in the epilysin promoter, as three
distinct protein/DNA complexes could be visualized in gel mobility shift assay. All three
complexes were efficiently competed by both an excess of unlabeled GT-probe and Sp1
consensus probe, but not by the mutated GT-probe. The proteins involved in these complexes
were identified by supershift assays. Antibodies specific for Sp1 recognized the largest
complex, whereas a Sp3-antibody recognized the two smaller complexes. These results
indicate that both Sp1 and Sp3 interact with the epilysin GT-box and hence could be
responsible for the positive effect on gene transcription mediated through the GT-box.
4.2 Cloning of mouse epilysin cDNA (II)
To clone the mouse homologue of epilysin, a mouse heart cDNA library was screened using a
human epilysin cDNA probe. A 1.5-kb fragment  was  selected  for  further  analysis  and
sequenced. Comparison of the obtained mouse sequence with the human epilysin cDNA
indicated that the fragment contained part of exon 2, exons 3-8, and ~800 bp of 3’-
untranslated region (UTR) of the mouse epilysin cDNA. The missing N-terminal sequence
was obtained by RT-PCR using RNA from GC-1 spg mouse spermatogonia as a template, a
forward primer located in the previously sequenced 5’-UTR of the mouse epilysin gene and a
reverse primer in the third exon. When comparing this sequence with the human epilysin
cDNA, we found that 30 nt in the beginning of the seventh exon were missing in the mouse
cDNA obtained from the cDNA library. To determine whether this sequence represents one of
several splice variants expressed in the mouse, we performed RT-PCR with primers on each
side  of  the  exon  border  and  RNA  from  GC-1  spg  mouse  spermatogonia  as  a  template.  In
addition to the expected PCR product representing the splice variant found in the library, two
other splice variants were identified (Fig. 1 in II). The major form represented full length
epilysin, corresponding to the human cDNA, and a minor form represented yet another splice
variant with 72 nt missing in the beginning of the seventh exon.
4.2.1 Mouse and human epilysin proteins are highly similar
The full length mouse cDNA contains an open reading frame of 1560 nt from the first ATG
codon, coding for a 520 aa protein with a calculated molecular weight of 59 kDa (Fig. 1 in II).
The predicted amino acid sequence of mouse epilysin includes several features typical for
MMPs. A hydrophobic signal sequence is followed by a propeptide including the
characteristic cysteine-switch sequence. In mouse epilysin this sequence (P89RCGVAD95)
differs from its human homologue in that it contains an alanine residue instead of a threonine
in position 94. The propeptide also contains an YGYL-sequence found in all membrane-
bound MMPs, but of the secreted MMPs only in MMP-19. The propeptide ends in a putative
furin recognition sequence RKKR. The catalytic center of both human and mouse epilysin,
HEIGHTLGLTH, differs from other MMPs in the respect that no other family member
contains threonine within this sequence. The catalytic domain is followed by a hinge region
and a typical hemopexin domain. Two potential N-glycosylation sites found in the catalytic
and hemopexin domains of human epilysin are conserved within the mouse homologue. The
detected alternative splicing of the seventh exon affects the hemopexin domain, deleting 10 or
24 amino acids from this domain but preserving the open reading frame (Fig. 1 in II). In the
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shortest splice variant the N-glycosylation site within the hemopexin domain is deleted. In
mouse epilysin 85 % of the amino acids are identical to the human protein with the highest
similarity in the catalytic domain (97 % identical residues).
4.2.2 Epilysin is processed by a furin-like pro-protein convertase
To assess if all three splice variants of mouse epilysin cDNA are translated to proteins,
expression constructs coding for the naturally occurring forms of the enzyme were generated
and transfected into CHO cells (constructs illustrated in paragraph 3.2.1).
Immunofluorescence studies of the transiently transfected CHO cells using epilysin specific
antibodies indicated that all three transcripts were translated to proteins that could be
visualized in the perinuclear area, presumably in the Golgi apparatus (Fig. 2 in II).
Immunoblotting analysis of conditioned media from these cells further showed that all splice
variants were secreted to the growth medium. In this transient system epilysin was expressed
only as one band of equal size in both growth medium and cell lysates, corresponding to the
approximate size of the proenzymes (Fig. 2 in II).
To analyze the secretion and processing of epilysin, we generated a stable HT-1080
fibrosarcoma cell line overexpressing recombinant mouse epilysin. Immunoblotting of the
conditioned medium using epilysin-specific antibodies revealed two bands of 48 and 58 kDa,
the 48 kDa band being more prominent (Fig. 3 in II). Treatment of the cells with a synthetic
furin inhibitor increased the intensity of the 58 kDa form at the expense of the shorter form.
Only the 58 kDa form was detected in cell lysates. To investigate whether recombinant mouse
epilysin is glycosylated, conditioned medium from cells overexpressing epilysin was treated
with N-glycosidase F (Fig. 4 in II). The apparent molecular weight of both the 48 and 58 kDa
forms were reduced by enzyme treatment. These results indicating that epilysin is activated
intracellularly by furin and that epilysin is N-glycosylated.
4.2.3 Epilysin is widely expressed in different tissues in the mouse
To determine the expression levels of epilysin mRNA in mouse tissues, RNA was extracted
from tissues of NMRI-mice and analyzed by RNase protection (Fig. 5 in II). Epilysin mRNA
was detected using a cRNA probe covering the exon border between exons six and seven,
where alternative splicing occurs, allowing for detection of the full length and intermediate
splice variants. Most of the analyzed tissues expressed detectable levels of epilysin mRNA,
the highest expression levels being in the lung and the placenta. The other organs expressing
moderate levels of epilysin were heart, salivary gland, thymus, uterus, testis, stomach, small
intestine, and colon. Expression levels were low in the developing embryo and in the adult
liver, kidney and brain. The full length mRNA was the predominant form in all tissues, and
the ratio of full length form to the shorter splice variants was constant. Expression levels were
low in the developing embryo and in the adult liver, kidney and brain. To determine the size
of the mouse epilysin transcript, an epilysin specific cDNA probe was hybridized to a
Northern blot containing mRNA from various mouse tissues (Fig. 6 in II). One transcript of
about 4.5 kb was detected and, as in the RNase protection analysis, most prominent
expression was seen in the lung. These results indicate that epilysin is normally expressed in
most tissues in the mouse.
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4.3 Epilysin induces epithelial to mesenchymal transition in lung
carcinoma cells (III)
To gain more information about the biological functions of epilysin we generated A549
human lung adenocarcinoma cell pools stably overexpressing wild type (wt) human epilysin
(Epi) and a catalytically inactive mutant of epilysin (Epi-E/A). During the selection process,
when the epilysin content of the cell pools was gradually increased, the morphology of the
cells was dramatically altered. The epithelial A549 cells expressing wt epilysin detached from
each other, elongated and adopted a fibroblast-like appearance consistent with EMT (Fig. 1 in
III). This change of phenotype was repeatedly observed in independent experiments. The cell
pools expressing the catalytically inactive mutant of epilysin showed no signs of EMT.
A hallmark of EMT is the loss of the cell surface adhesion protein E-cadherin. No E-
cadherin could be detected on the surface of cells expressing wt epilysin that had undergone
EMT,  but  the  E-cadherin  staining  on  the  cell  surface  of  control  and  Epi-E/A  pools  was
abundant (Fig.  1 in III).  Accordingly,  increased levels of the shed 80 kDa ectodomain of E-
cadherin were detected in the conditioned medium of epilysin expressing cells. These results
indicate that enhanced E-cadherin shedding and loss of E-cadherin mediated cell-cell
adhesion  coincide  with  the  transition  of  epilysin  expressing  A549  cells  from  epithelial  to
mesenchymal cell morphology.
4.3.1 TGF-b mediates the epilysin-induced EMT
Because  of  the  well  known  capacity  of  TGF-b to  initiate  and  maintain  EMT  we  next
determined the levels of active and total TGF-b in the A549 cell pools using the mink lung
epithelial cell (Mv1Lu) indicator assay. The levels of both active and total TGF-b were
markedly increased in the medium of epilysin expressing cells (Fig. 2 in III). Mature TGF-b
remains latent through association with LAP, which can be sequestered to the ECM through
association with the LTBPs. Latent TGF-b can be activated by proteolytic processing of the
latent complex. To determine whether processing of large latent TGF-b complexes takes place
in the epilysin expressing pools, antibodies specific for latent TGF-b1 complexes and for
LTBP-1 were used to identify polypeptides from their conditioned medium (Fig. 2 in III). The
results revealed only degraded TGF-b1 complexes in the medium from the wt epilysin
expressing cell pool, whereas only intact large latent complexes were detected in the medium
from the control and Epi-E/A pools. Similarly, LTBP-1 was truncated and digested in the
epilysin pool whereas TGF-b containing large LTBP-1 complexes were found in both the
control and Epi-E/A pools. Taken together, these results reveal proteolytic degradation of
latent TGF-b1/LTBP-1 complexes in cultures of the transformed epilysin expressing pool,
evidently resulting in the enhanced secretion and activation of TGF-b.
We next attempted to determine whether the increase in TGF-b activity was the cause
or consequence of EMT. For this purpose we selected A549 cell pools stably expressing
epilysin in the constant presence of the synthetic MMP inhibitor GM6001. We found that
transformation of the epilysin expressing cells could not be reversed by GM6001, but addition
of the inhibitor already at the initiation of the selection procedure significantly delayed the
epilysin-induced EMT. To further characterize the epilysin-induced EMT these
untransformed epilysin expressing cells were changed to medium supplemented with
antibodies neutralizing the activity of either TGF-b or HGF or left with GM6001 or without
any supplements (Fig. 3A in III). After 72 h, as expected, the TGF-b levels in pools kept with
GM6001 were comparable to those of the control and Epi-E/A pools and the cells showed no
phenotypic alterations at this point. The cells incubated with neutralizing anti-TGF-b
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antibodies similarly retained their normal epithelial morphology and low total TGF-b levels.
On  the  contrary,  the  pools  incubated  either  without  any  supplements  or  with  the  anti-HGF
antibodies revealed an increase in the levels of both active and total TGF-b. These cells also
showed alterations characteristic of EMT in their morphology as they started to detach from
each other and elongate within 72 h. Next, the cells were stained with antibodies specific for
E-cadherin and the phosphorylated form of the TGF-b signaling molecule Smad-2 (P-Smad-
2) (Fig. 3B in III). Smad-2 is phosphorylated in response to TGF-b stimulation through TGF-
b receptors on the cell surface and is an essential mediator of TGF-b-induced EMT in tumor
progression. The results revealed that cells with abundant E-cadherin staining on the surface
simultaneously showed weak staining for nuclear P-Smad-2, in contrast to the E-cadherin
negative cells that in general showed a more prominent nuclear P-Smad-2 staining. Counting
of the E-cadherin positive cells showed more positive cells in the GM6001 and anti-TGF-b
treated  pools  as  compared  to  the  cells  incubated  without  any  supplements  or  with  the  anti-
HGF antibodies, whereas the results for P-Smad-2 positive cells were the contrary. These
results indicate that neutralizing anti-TGF-b antibodies, like the MMP inhibitor GM6001, can
antagonize epilysin-induced EMT in A549 cells revealing TGF-b as a critical mediator of this
process.
4.3.2 Induction of gelatinase B and MT1-MMP in epilysin-induced EMT
Given the ability of several MMPs to activate other MMPs, we next determined the levels of
stromelysin-1 and matrilysin, whose functions have been linked to the shedding of E-
cadherin, in the different cell pools. No stromelysin-1 was immunodetected in the medium
from any of the cell pools. A faint band likely to represent matrilysin was detected in all the
media, but no major difference could be detected between the different pools (Fig. 4A in III).
Thus the epilysin-induced E-cadherin degradation is not likely to involve stromelysin-1 or
matrilysin activation or activity. Further, the alternatively spliced form of the small GTPase
Rac1 (Rac1b) that underlies stromelysin-1-induced EMT could not be detected by RT-PCR in
any of the pools suggesting that the TGF-b dependent EMT mechanism adopted by the
epilysin expressing cells is distinct from the one adopted by stromelysin-1. Among MMPs,
gelatinases A and B and MT1-MMP have been suggested to mediate TGF-b activation  and
invasion of transformed cells. Interestingly, both MT1-MMP and gelatinase B were
significantly increased in the epilysin expressing cell pool (Fig. 4B and C in III).
4.4 Epilysin is associated with the surface of epithelial cells (III)
To determine how the structure of epilysin is related to its function, we carried out transient
transfection experiments of A549 lung adenocarcinoma cells with expression constructs
coding for wt epilysin (Epi*), a catalytically inactive mutant of epilysin (Epi-E/A*) and
deletion constructs containing either the pro and catalytic domains (Cat*) or the hemopexin
domain (Pex*) of epilysin, all with C-terminal V5(*)-tags (constructs illustrated in paragraph
3.2.1). Immunoblotting analyzis of the conditioned medium and cell lysates showed that all
the recombinant proteins were detectable in both (Fig. 5B in III). The wt and E/A forms of
epilysin were mostly found in the active form but also in the proenzyme form. As expected,
the Cat* protein was also detected in both pro and active forms, whereas the Pex* protein
migrated as one band.
Although epilysin itself does not contain a transmembrane domain or membrane
anchoring sequence, immunofluorescence analysis of the transfected cells showed that
epilysin, as well as the Pex* protein and the inactive Epi-E/A* mutant, were localized on the
48
cell surface (Fig. 5C in III). In contrast, the protein containing only the catalytic domain was
not detectable on the cell surface, indicating that the hemopexin domain is sufficient for this
interaction. Recombinant epilysin was localized on the cell surface also in the other examined
cell lines of epithelial origin, whereas no recombinant epilysin could be detected on the
surface of HT-1080 fibrosarcoma cells, suggesting that epilysin is bound to the cell surface
through an epithelial cell specific structure.
4.4.1 Cell surface association of epilysin is lost upon EMT
In contrast to the abundant cell surface expression observed in the transiently transfected
cells, epilysin was not detected by specific antibodies on the surface of the stable cell pools
that had undergone EMT (Fig. 6 in III). The catalytically inactive E/A mutant displayed,
however, abundant cell surface expression also in the stable pools. Addition of GM6001 to
the transformed wt expressing pool, which did not reverse the transformed phenotype, did not
either restore epilysin on the cell surface. These results indicated that either the turnover of
epilysin  on  the  surface  of  the  transformed  cells  was  more  rapid  than  that  of  the  Epi-E/A
mutant in the cells displaying an epithelial phenotype or that the receptor attaching epilysin to
the cell surface was downregulated during EMT.
In transient transfection experiments, the transfection of epilysin with relatively low
efficiency (5-10 % transfected cells, Fig. 5 in III) did not result in significant TGF-b
induction,  and  the  morphological  cell  transformation  was  also  less  clear  than  in  the  wt
epilysin expressing stable cell pools. Interestingly, immunofluorescence analysis of A549
cells transiently cotransfected with different epilysin and MT1-MMP constructs showed that
all cells expressing MT1-MMP on the cell surface were negative for epilysin (Fig. 5D in III).
Coexpression of epilysin and MT1-MMP could, however, be detected on the cell surface in
the presence of GM6001 or when the catalytically inactive mutant of MT1-MMP (MT1-E/A)
was expressed. These results indicate that either epilysin or its cell surface receptor is
destabilized or degraded by MT1-MMP. Indeed, in the progress of EMT the induction of
MT1-MMP may cause the observed loss of cell surface bound epilysin.
4.5 Epilysin increases the motility of lung carcinoma cells (III)
A characteristic feature of EMT is the increased motility of the transformed epithelial cells.
To determine whether epilysin can affect cell motility, transiently transfected A549 cells and
stable A549 cell pools were seeded on type I collagen coated cell culture inserts. After 4 h,
the cells that had migrated to the lower side of the membrane were fixed and counted. The
results showed a marked increase in the migration of both transient and stable epilysin
expressing  cells  over  control  transfectants  (Fig.  7  in  III).  In  contrast,  the  expression  of  the
catalytically inactive Epi-E/A mutant did not increase the migration of the A549 cells in either
case. Interestingly, the MMP inhibitor GM6001 markedly decreased the number of the
migrated, transiently transfected, epilysin expressing cells, but did not have a significant
effect on the migration of the stable epilysin expressing A549 cell pool. On the contrary,
transient transfection of epilysin into HT-1080 cells, which normally display mesenchymal
morphology, did not affect their migration. These results suggest that epilysin-induced cell
transformation from a quiescent to a motile phenotype rather than cell migration itself
requires MMP activity.
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4.5.1 Epilysin-induced EMT results in a collagen invasive phenotype
A critical feature of transformed and mesenchymal cells is their ability to invade collagen rich
tissues. To define whether the epilysin-induced EMT provides the cells with the means to
invade collagen matrices, transiently transfected A549 cells and stable A549 cell pools were
seeded on top of type I collagen gels in cell culture inserts. After 8 days in culture, prominent
invasion of transformed epilysin expressing cells into the underlying collagen was observed
by microscopy of HE-stained paraffin sections (Fig. 8A in III). In contrast, no invading cells
were found in the control or Epi-E/A cell pools. The MMP inhibitor GM6001 significantly
inhibited the invasion of the transformed epilysin expressing cells. Consistent with the less
evident transformation of the phenotype and absence of TGF-b induction in cells transiently
transfected with epilysin, only a few of these had invaded into the collagen gel (Fig. 8B in
III). The few invaded cells, however, all showed a transformed phenotype as determined by
microscopically examining the appearance of the cells. In accordance with the previously
identified role of MT1-MMP in collagen invasion, the transiently MT1-MMP transfected
A549 cells invaded readily into the collagen gel. Taken together these results show that
epilysin-induced EMT provides the cells with collagen invasive properties.
4.6 Central findings of the work
The most important findings of the current study are summarized in Fig. 7.
Figure 7. Summary of the results: Transcription  factors  Sp1  and  Sp3  bind  to  a  conserved  GT-box  in  the
epilysin promoter (1); proepilysin is activated by furin (2); overexpression of epilysin leads to the degradation of
large latent TGF-b complexes and a subsequent increase in active TGF-b (3) and induction of EMT (4), loss of
cell surface E-cadherin (5) and upregulation of MT1-MMP and gelatinase B (6). The two-headed arrows indicate
that the internal order and causality of the events involved in the epilysin-induced EMT process is not known.
Epilysin is bound to the cell surface by an unknown receptor (7). This cell surface association is lost upon EMT
(8) and susceptible to cleavage by MT1-MMP (9).
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5 Discussion
5.1 Regulation of epilysin gene expression (I)
Individual and stringent regulation of the expression of Mmp genes has been pointed out as an
important means of targeting the actions of these potent proteases to suitable substrates in the
correct location and time frame (Ra and Parks, 2007). To gain knowledge about the regulation
of epilysin gene expression we have sequenced and characterized the promoters of the human
and mouse epilysin genes, and compared their structure and function. Computer analysis of
the human and mouse epilysin promoter sequences revealed several putative binding sites for
known transcription factors. Most notably, a GT-box with homology to the consensus binding
site for the Sp-family of transcription factors was found about 70 bp upstream from the
transcription initiation site. This site is perfectly conserved between the human and mouse
promoters, implying a central role for this sequence in the regulation of gene expression. The
importance of this GT-box was verified by the fact that mutation or deletion of the GT-box
significantly reduced the transcriptional activity of reporter gene constructs in both
keratinocytes and spermatogonia. Gel mobility and supershift assays revealed that the
transcription factors Sp1 and Sp3 bind this GT-box sequence in vitro (I).
5.1.1 Specific regulation of gene expression by Sp1 and Sp3
The Sp-family of transcription factors includes four zinc finger DNA binding proteins, of
which Sp1 and Sp3 are ubiquitously expressed in a wide variety of tissues and hence regulate
numerous genes including common housekeeping genes. Regulation of gene expression by
the Sp-family can, nevertheless, be strictly controlled allowing for cell type specific and cell
cycle and developmental stage specific variations in gene expression (Li et al., 2004a). Sp1
and Sp3 are highly homologous and both bind to the same consensus sequence, so called GC-
or GT-boxes, in the proximal promoters of target genes (Suske, 1999). Sp1 usually functions
as an inducer of transcription whereas Sp3 either induces or represses transcription. The ratio
of Sp1 to Sp3 is therefore an important means of regulating transcription, and variations in
this ratio can be observed during cell cycle progression and cell differentiation (Li et al.,
2004a). During differentiation of primary keratinocytes the initially high Sp3/Sp1 ratio is
reversed inducing the transcription of epithelial specific genes such as E-cadherin (Apt et al.,
1996), which contains several potential GC/GT-boxes within its promoter (Liu et al., 2005).
The cell type and differentiation stage specific regulation of Sp target genes in keratinocytes
is of specific interest, as epilysin was originally cloned from a keratinocyte cDNA library and
the protein is expressed in primary and transformed keratinocytes (Lohi et al., 2001).
During dermal wound healing, epilysin expression is strongly upregulated in
hyperproliferative basal and suprabasal keratinocytes distal from the wound edge (Lohi et al.,
2001; Saarialho-Kere et  al., 2002). Wound healing of the corneal epithelium is initiated by
massive secretion of fibronectin that is later replaced by laminin. During the healing process,
these ECM proteins have been implicated in the regulation of the expression of the a5 and a6
integrin subunits through alterations in the levels of Sp1 and Sp3 (Gingras et al., 2003;
Gaudreault et al., 2007), suggesting that these factors could be used more widely for
coordinating gene expression during wound repair. Differentiation stage specific regulation of
gene transcription by Sp1 is also crucial in male germ cell development (Thomas et al., 2007),
and in embryogenesis (Marin et al., 1997). In view of data on gene regulation by Sp1 and Sp3
it appears likely that the regulation of the epilysin promoter through its Sp1/Sp3 binding GT-
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box may be of central importance for both the basal and cell type specific expression of
epilysin.
5.1.2 Sp1 and Sp3 are mediators of TGF-b-induced gene regulation
Sp1 and Sp3 regulate gene expression by functionally cooperating with other proteins, such as
other transcription factors and chromatin remodeling factors (Li et al., 2004a). Interestingly,
Sp1 interacts directly with transcriptional regulators of the Smad-family, an association that is
induced by TGF-b signaling and results in enhanced DNA binding. Sp1 has thus been
recognized as an important factor in the induction of many TGF-b regulated genes
(Moustakas et al.,  2002).  The  ratio  of  Sp1 to  Sp3 also  critically  regulates  the  expression  of
TGF-b receptor II, as Sp1 enhances while Sp3 represses its expression. Overexpression of
Sp3 has therefore been indicated as one mechanism adopted by different cancer cells to
circumvent the growth inhibitory effects of TGF-b (Safe and Abdelrahim, 2005).
Interestingly, a recent report proposed that Sp1, in cooperation with activated Smads, is a
crucial mediator of TGF-b-induced EMT in pancreatic cancer cells, as abrogation of Sp1 in
this cell system prevented migration but not proliferation of the transformed cancer cells
(Jungert et  al., 2007). As we have found that epilysin induces EMT in lung carcinoma cells
through mechanisms depending on TGF-b and involving the activation of Smad-2 (III), these
observations raise the question whether TGF-b is involved in the regulation of the epilysin
gene through its functional Sp1/Sp3-binding site (I) and whether epilysin could function both
as an inducer and effector of TGF-b signaling. This assumption is supported by the report of a
slight induction of epilysin expression detected by real time PCR in primary keratinocytes
treated with TGF-b1 (Saarialho-Kere et al., 2002).
Another link between epilysin and TGF-b in EMT involving Sp1 was revealed by
studies concerning the transcription factor Snail. Snail is a critical regulator of EMT
(Barrallo-Gimeno and Nieto, 2005) and the most important downstream target of TGF-b
signaling in EMT (Peinado et al., 2003). Snail induces EMT through numerous target
molecules (De Craene et al., 2005), most importantly through repressing the expression of the
cell-cell adhesion molecule E-cadherin (Batlle et al., 2000; Cano et al., 2000). Among the
MMPs, in vitro induction of gelatinase A, matrilysin and MT1-MMP by Snail have been
reported (Yokoyama et al., 2003; Miyoshi et al., 2004). When overexpressed in MDCK cells,
Snail induces expression of gelatinase B as part of the EMT process (Jorda et al., 2005). Snail
does not seem to interact directly with the gelatinase B promoter, but the binding of Sp1 to a
specific GC-box within the promoter is required for induction.
5.1.3 Histone deacetylation inhibitors affect epilysin expression
Histones are nuclear proteins involved in the packaging of DNA in the eukaryotic nucleus.
The histones can be modified by regulating their state of acetylation by histone
acetyltransferases (HATs) and histone deacetylases (HDACs) that reversibly add and remove
acetyl groups from their specific lysine residues. Acetylation neutralizes the positive charge
of the histones, thereby loosening the histone-DNA interaction and allowing access of
transcription factors. In addition, the activity of many other proteins such as structural
proteins, intracellular signaling molecules and transcription factors is modulated by
acetylation (Clark et al., 2007). It has recently been proposed that epilysin is one of a small
subset of Mmp genes that is induced by treatment with HDAC inhibitors, in contrast to most
other Mmp genes that are repressed by these inhibitors (Young et al., 2005). Using our
promoter constructs, Swingler et al. (submitted, 2007) reported that this induction depends on
the GT-box we identified (I). They proposed that overexpression of Sp1, but not Sp3, induces
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promoter constructs containing the GT-box in vitro, and that this induction is further
promoted by HDAC inhibitors. Sp1, rather than histones, may in this experimental setup be
the target affected by the HDAC inhibitors, as the activity of Sp1 is regulated by acetylation
of the transcription factor itself (Li et al., 2004a). By chromatin immunoprecipitation it was
found that Sp1 associates with the GT-box in vivo, and by oligonucleotide pulldown
experiments association of the serine threonine receptor associated protein (STRAP) with the
GT-box in the epilysin promoter was further detected (Swingler et al., submitted 2007).
STRAP  associates  with  both  type  I  and  II  TGF-b receptors and inhibits TGF-b-induced
transcriptional responses in synergy with Smad-7 (Datta et  al., 1998; Seong et al., 2007).
These findings provide yet another link between TGF-b and the regulation of epilysin
expression.
Other Mmp genes including binding sites for Sp1/Sp3 in their promoters are gelatinases
A (Huhtala et al., 1990) and B (Huhtala et al., 1991) and MT1-MMP (Lohi et al., 2000). The
Timp-2 gene also contains binding sites for Sp1/Sp3 (Hammani et al., 1996) as does the gene
coding for the cell surface-bound MMP inhibitor RECK (Sasahara et al., 1999). Of these,
gelatinase A is repressed whereas TIMP-2 is induced by HDAC inhibitors. The expression of
gelatinase B is either repressed or induced, depending on the cellular context (Clark et al.,
2007). The expression of RECK is, like epilysin, repressed by HDACs, a repression mediated
through the Sp1 binding site (Chang et al., 2004). These observations highlight the possibility
to modify the regulation exerted by Sp1/Sp3 on Mmp gene expression by acetylation, and
further emphasize the importance of the Sp1/Sp3 binding site in the epilysin promoter.
However, all these studies have been conducted at least partly in vitro, and many other factors
may influence the transcriptional activity in vivo.
5.2 Epilysin is highly conserved between species (II)
Information on the specific tissues and circumstances under which a proteinase is expressed is
essential to determine its function. After all, simply characterizing the enzyme’s ability to
cleave possible substrates in vitro does not necessarily reflect a relevant biological function.
To explore the in vivo expression and to gain insight into the biological functions of epilysin,
we cloned the mouse homologue of the epilysin cDNA and characterized its expression in a
variety of tissues. The predicted mouse protein is highly similar to the human enzyme,
including the “cysteine switch” sequence in the prodomain, the conserved furin recognition
sequence, and the unique catalytic site sequence (II). Between the human and mouse proteins,
85 % of the overall amino acid residues and 97 % in the catalytic domain, are identical
indicating a well-conserved function for this enzyme. This assumption is further supported by
the observation that epilysin is well conserved also in Xenopus laevis, as 56 % of the overall
amino acids in XMMP-28 and 65 % in the catalytic domain are identical with human epilysin
(Werner et al., 2007). We observed that the potential furin recognition motif at the end of the
prodomain is functional, proposing intracellular cleavage of epilysin by the proprotein
convertase furin as an important point of regulating enzyme activity. The furin site is also
conserved and functional in XMMP-28 (Werner et al., 2007). All the MT-MMPs are activated
by furin, whereas stromelysin-3 is the only other furin-activated soluble MMP.
We identified an YGYL sequence in the prodomain of epilysin that is conserved in the
human as well as the Xenopus protein. Interestingly, a corresponding sequence in the
prodomain of MT1-MMP has been proposed to confer the prodomain the capacity to serve as
a chaperone regulating the folding and trafficking of the enzyme (Cao et al., 2000; Pavlaki et
al., 2002). This sequence is common to all MT-MMPs, but among the other secreted MMPs
only MMP-19 contains this sequence (Cossins et  al., 1996; Pendas et al., 1997). There are,
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however, no reported functions for the YGYL sequence in other MMPs apart from MT1-
MMP  or  in  any in vivo model, rendering the relevance of this sequence in the epilysin
prodomain uncertain.
We further detected alternative splicing of the epilysin mRNA, producing two shorter
in-frame splice variants with 10 and 24 amino acids missing from the hemopexin domain,
respectively. Alternative splicing affects the second blade of the four-bladed-propeller-like
hemopexin domain, and may thus affect its substrate interactions. The splice variants were
detected also in tissues from NMRI mice, but the ratio of shorter splice variants to full length
mRNA was constant and low, excluding the possibility for tissue specific functions of these
splice variants. No corresponding variants of the human mRNA could be detected further
questioning the relevance of alternative splicing in the regulation of epilysin function in vivo.
Another form of alternative splicing of the human epilysin mRNA has, however, been
detected generating a shorter mRNA where part of the catalytic domain is missing. In general,
alternative  splicing  of  MMPs  is  an  unusual  feature  as  there  are  only  a  few  reports  on  this
phenomenon (MT3-MMP, Matsumoto et al., 1997; collagenase-2, Hu et al., 1999;
stromelysin-3, Luo et al., 2002).
5.2.1 Epilysin is expressed in normal tissues
Tissue expression of epilysin in adult, healthy NMRI mice was determined by RNase
protection and Northern hybridization. Epilysin mRNA was detected in various tissues with
highest expression levels in the lung. Epilysin mRNA was also detected in the placenta, heart,
uterus, testis and gastrointestinal tract. Expression levels were low in the developing embryo
and in the adult liver, kidney and brain. In addition to our observations, there is an other
report  on the expression of epilysin mRNA in mouse embryos (Werner et al., 2007), where
the authors report a peak of epilysin expression at E14 in the developing neural system, in
both the CNS and peripheral nerves. By in situ hybridization epilysin mRNA was detected in
the rhesus monkey uterus during early pregnancy (Li et al., 2003a). The tissue distribution of
mouse epilysin mRNA resembles that of human epilysin with one notable exception: in adult
human tissues the most prominent expression was found in the testis (Lohi et  al., 2001),
whereas the overall expression levels in the adult mouse testis were only moderate. The wide
expression of epilysin is in agreement with the induction of the epilysin gene by the common
transcription factor Sp1. This expression pattern, however, distinguishes epilysin from most
other MMP-family members, as most MMPs are expressed only under exceptional conditions
such as those related to injury, inflammation or disease (Ra and Parks, 2007). The expression
pattern implicates a role for epilysin in normal tissue homeostasis and turnover and thus sets a
basis for the future efforts to characterize its biological functions and substrates.
5.2.2 Matrilysin, MMP-19 and epilysin are epithelial MMPs
Epilysin is expressed solely by epithelial cells in human skin (Lohi et al., 2001; Saarialho-
Kere et al., 2002), and in the mouse uterus epilysin mRNA is expressed exclusively in the
endometrium (Illman, S.A., unpublished observation). It is therefore reasonable to speculate
that epilysin is expressed in the epithelial compartment also in other tissues. Two other MMPs
that have been detected in intact healthy epithelia are matrilysin and MMP-19. Further,
stromelysin-2 is expressed exclusively in epithelial cells, but only in response to injury or in
carcinomas and not under normal conditions (Saarialho-Kere et al., 1994; Madlener et al.,
1996). Matrilysin is expressed in several mucosal epithelia, such as the small intestine, lung
and exocrine glands, but not in the epidermis (Saarialho-Kere et  al., 1995; Wilson et al.,
1995). MMP-19, on the contrary, is expressed in basal keratinocytes in the epidermis (Impola
et al., 2003; Sadowski et al., 2003b) and in several other tissues (Pendas et al., 1997).
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Matrilysin functions in important processes involved in protecting epithelial tissues (Parks et
al., 2004), such as in the defense against bacteria in the intestine (Wilson et al., 1999) and in
re-epithelialization in the process of healing lung injury (McGuire et  al., 2003). These are
indeed biologically relevant functions for matrilysin, since both processes are defective in
matrilysin deficient mice. Matrilysin is, however, also involved in the progress of cancer in
vivo and is frequently detected in cancers of almost all human organs (Wielockx et al., 2004).
MMP-19, on the other hand, has been detected in proliferating but not in invasive SCC
cells (Impola et al., 2003; 2005), findings that are further supported by a report on the
expression of MMP-19 at the invasive front in early but not later stages of SCC carcinomas
(Sadowski et al., 2005). Similarly, MMP-19 is expressed in the normal epithelium of both the
mammary gland (Djonov et al., 2001) and colon (Bister et al., 2004), but is downregulated in
both tissues upon malignant transformation. In dermal wounds, MMP-19 is detected in
keratinocytes outside the migrating area (Impola et al., 2003). MMP-19 increases cell
proliferation, migration and adhesion to collagen I in vitro through the cleavage of IGFBP-3
and subsequent release of IGF (Sadowski et al., 2003a). Further, MMP-19 is downregulated
by transcription factors Tst-1 and Skn-1 that promote keratinocyte differentiation and
decrease proliferation (Beck et al., 2007). The generation of MMP-19 deficient mice has,
however, revealed an unexpected function for this protease in the regulation of adipogenesis,
as MMP-19 deficient mice develop diet-induced obesity (Pendas et al., 2004). No effects on
IGF release could, however, be detected in this model. The effect of MMP-19 on cancer
progression is controversial. MMP-19 deficient mice develop fewer fibrosarcomas in their
skin after treatment with carcinogens (Pendas et al., 2004), whereas tumor angiogenesis and
invasion are promoted in the same mice when compared to wt (Jost et al., 2006). These
results may reflect the different functions of MMP-19, and MMPs in general, in different
forms of cancer and in different stages of tumor progression (Martin and Matrisian, 2007).
The role of epilysin in cancer also appears contradictory, as there are reports on both
increased and decreased epilysin expression in different tumors (section 1.2.3.2). A functional
role for epilysin has, however, been described in OSCC, where the expression of epilysin
mRNA was markedly upregulated (Lin et  al., 2006). Secretion of epilysin from OSCC and
esophageal carcinoma cells was reduced by capturing epilysin mRNA with antisense
oligodeoxynucleotides, which impaired the ability of these cells to form colonies in soft agar
without affecting cell growth. These results indicate a role for epilysin in the anchorage-
independent growth of both OSCC and esophageal carcinomas. The effect of downregulating
epilysin on the invasive capacity of these cells was not determined (Lin et al., 2006).
However, in another study, epilysin immunoreactivity was detected in proliferating basal and
suprabasal keratinocytes in grade I SCC from the skin, but not in aggressive cutaneous
sclerosing  basal  carcinomas  or  SCCs  of  grades  II  and  III  (Saarialho-Kere et al., 2002).
Epilysin, like MMP-19, thus seems to be involved in cancer cell proliferation in early stages
of SCC and downregulated in invasive higher grade carcinomas. Similar observations have
been made in colon carcinomas (Bister et al., 2004) and melanomas (Kuivanen et al., 2005),
whereas upregulation of epilysin expression in invasive carcinomas of the breast (Overall et
al., 2004) and bladder (Wallard et al., 2006) have been observed. Epilysin may, therefore, like
MMP-19  play  different  roles  in  cancers  of  different  tissues  and  at  various  stages  of  cancer
progression.
Another similarity among the epithelial MMPs is that they are associated with the cell
surface through interactions with different cell surface receptors. Matrilysin associates with
heparan sulfates (Yu and Woessner, 2000; Yu et  al., 2002), cholesterol (Yamamoto et al.,
2006) and the tetraspanin CD151 (Shiomi et al., 2005), whereas the cell surface receptor for
MMP-19 is unknown (Sadowski et al., 2005). We have observed that epilysin associates with
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a so far uncharacterized MT1-MMP sensitive cell surface receptor (III), illustrating the
importance of compartmentalization for proper MMP function.
5.2.3 Targeted disruption of the epilysin gene in the mouse
Despite the similar expression patterns of the epithelial MMPs, matrilysin, MMP-19 and
epilysin  all  seem  to  display  distinct  functions.  To  further  characterize  the  specific  role  of
epilysin in this triad, we have recently generated a mouse model where the epilysin gene has
been disrupted. Initial observations show that the mice breed normally and are born with no
obvious phenotype. When its lungs were challenged by different inflammatory agents the
epilysin mRNA levels were markedly downregulated in the wt mice (Parks, W.C., personal
communication, 2007). The KO mice, on the contrary, show a rapid influx of macrophages
into the lungs after infection and altered levels of cytokines and chemokines. The results
implicate that epilysin may serve a function in the immune response, an assumption that is
supported by the reported induction of epilysin expression in primary keratinocytes by the
pro-inflammatory cytokine TNF-a (Saarialho-Kere et al.,  2002).  Interestingly,  a  recently
cloned MMP from the lepidopteran model Galleria mellonella has been implicated in the
activation of innate immunity in this organism. This MMP, named Gm1-MMP, shares highest
similarity with human MMP-19 and epilysin (Altincicek and Vilcinskas, 2006; 2007).
Among the epithelial MMPs also matrilysin is importantly involved in many aspects of
the immune system (Parks et al., 2004) and mice deficient in stromelysin-2 develop much
more severe pneumonia upon bacterial infection (Kassim et al., 2007). The healing of skin
wounds of epilysin deficient mice appears normal and no abnormalities in either wound
closure rate or wound histology have been revealed (Illman, S.A., unpublished observations).
A possible role for epilysin in wound healing is cannot be excluded as other MMPs may
compensate for the lack of epilysin.
5.3 Epilysin induces TGF-b mediated EMT in lung carcinoma cells (III)
Considering the detection of epilysin in the epithelia of several intact, healthy tissues (Lohi et
al., 2001; II) our unexpected observation that the expression of epilysin causes stable EMT in
A549 lung adenocarcinoma cells (III) points out a novel role for epilysin in the regulation of
epithelial cell phenotype. Consistent with this epithelial cell specific function, a similar
phenomenon was observed also in MDCK kidney epithelial cells, whereas epilysin expression
caused no observed effects on the morphology and migration of HT-1080 fibrosarcoma cells.
Interestingly, an inactivating point mutation of epilysin (E241A), the MMP inhibitor
GM6001, and neutralizing antibodies against TGF-b all  prevented  the  onset  of  EMT,
indicating that this is a TGF-b mediated process triggered by the catalytic activity of epilysin.
The epilysin-induced EMT was irreversible as the altered phenotype was maintained despite
the subsequent addition of the MMP inhibitor.
Members of the TGF-b family can induce and maintain EMT in a variety of biological
and pathological systems like wound healing, cancer and fibrosis (Zavadil and Böttinger,
2005). Interestingly, we observed proteolytic degradation of latent TGF-b complexes
accompanied by increased levels of both active and latent TGF-b in the morphologically
altered epilysin expressing cell pool. These changes were accompanied by increased
phosphorylation of the TGF-b signaling molecule Smad-2, an event suggested to be crucial in
TGF-b-induced EMT in cancer progression (discussed in Lee et al., 2006). Neutralizing anti-
TGF-b antibodies, as well as the MMP inhibitor GM6001, prevented the epilysin-induced
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release  of  active  TGF-b and  soluble  TGF-b complexes and hence prevented EMT in the
overexpressing cell pools.
In accordance with increased TGF-b signaling, the mRNA levels of the transcription
factor Snail were upregulated about 1.5-fold in the epilysin expressing cell pool. Snail is a
downstream target of TGF-b signaling (Peinado et al., 2003) and a critical regulator of EMT
(Barrallo-Gimeno and Nieto, 2005). Snail induces EMT through numerous target molecules
(De Craene et al., 2005). Among these we found upregulation of gelatinase B (Jorda et al.,
2005) and MT1-MMP (Miyoshi et al., 2004) in the morphologically altered cells. By contrast,
the expression of gelatinase A was downregulated in these cells further highlighting the
extensive change in the MMP expression profile upon this transcriptional EMT program.
Interestingly, both gelatinase B and MT1-MMP have the ability to activate TGF-b, at least in
vitro, by direct cleavage of the LAP complex (Yu and Stamenkovic, 2000; Mu et al., 2002).
Further investigations aiming at the identification of direct epilysin substrates will illuminate
the more exact cascade of events leading to TGF-b activation and EMT. Current results,
nevertheless, indicate that transient activity of epilysin is sufficient to induce a coordinated
TGF-b dependent program leading to the loss of the epithelial  phenotype and to the gain of
characteristics of invasive cancer cells.
With some analogy to these results stromelysin-1 can also initiate EMT (Lochter et al.,
1997; Radisky et  al., 2005), and both stromelysin-1 and matrilysin can cleave E-cadherin
(Noë et al., 2001), which is a critical event in the onset of EMT (Thiery, 2002). In contrast to
our results, however, stromelysin-1-induced EMT is mediated by Rac1b and ROS, but does
not involve TGF-b. Therefore, even though we find here that the epilysin-induced EMT also
involves E-cadherin shedding, the mechanism by which epilysin induces EMT differs from
that of stromelysin-1. Further, we observed that the epilysin-induced EMT does not involve
the activation of either stromelysin-1 or matrilysin. MT1-MMP and gelatinase B, on the other
hand, have both been shown to mediate the shedding of E-cadherin in ischemic kidney NRK
cells (Covington et al. 2006) and epithelial ovarian carcinoma cells (Symowicz et al., 2007),
respectively. As we detected induction of both of these MMPs upon epilysin-induced EMT
(III), MT1-MMP and gelatinase B may be responsible for the observed E-cadherin shedding.
Interestingly, recombinant XMMP-28 (the epilysin homologue in Xenopus laevis) can digest
another cell adhesion molecule, the synaptic membrane glycoprotein NCAM, in vitro (Werner
et al., 2007).
5.3.1 Epilysin induces epithelial cell motility
MMPs exhibit a considerable overlap in their in vitro substrates. In vivo substrate specificity
is determined by the regulation of their affinity towards different substrates and by strict
temporal and spatial regulation of the active proteases, so called compartmentalization (Ra
and Parks, 2007). Even though most MMPs are secreted as soluble molecules, many of them
can interact with specific receptor molecules on the cell surface to direct their proteolytic
activity to specific sites in the pericellular environment (Brooks et  al., 1996; Dumin et al.,
2001; Yu and Stamenkovic, 1999; Yu and Woessner, 2000; Yu et al., 2002). Current data
indicate that epilysin, though lacking a transmembrane domain, associates with the surface of
epithelial cells through mechanisms involving the hemopexin domain. Accordingly, high
molecular weight complexes containing epilysin can be detected on the surface of A549 cells
that have not undergone EMT yet (Illman, S.A., unpublished observation). These results
identify spatial targeting of epilysin as a novel means of regulating its activity and bringing it
into close proximity of potential cell surface targets in epithelial cells.
Directed pericellular proteolysis is crucial in cell migration and invasion through the
ECM (Murphy and Gavrilovic, 1999). The morphologically altered A549 cells stably
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overexpressing epilysin gained enhanced ability to migrate through type I collagen coated
membranes. However, the enhanced migration was not inhibited by GM6001 indicating that
epilysin is required only transiently for the epithelial cells to acquire the migratory phenotype,
whereas the transwell migration itself was independent of MMP activity. Invasion of both
fibroblasts and tumor cells into cross-linked collagen gels in vitro as well as into the chicken
chorioallantoic membrane in vivo, on the other hand, are both processes dependent on the
catalytic activity of MT1-MMP (Hotary et al., 2000; Sabeh et al., 2004). However, invasion
of carcinoma cells into in vivo BMs obtained from mouse peritoneum can be driven by the
catalytic activity of either MT1-, MT2-, or MT3-MMP (Hotary et al., 2006). We found that
A549 cells transiently expressing MT1-MMP invaded readily into collagen gels, as did the
stable  epilysin  expressing  cells  that  had  undergone  EMT.  The  collagen  invasion  of  all  cells
was inhibited by GM6001 emphasizing the role of MMPs in the process. It has not been
determined yet whether epilysin itself possesses any collagenolytic activity. However, as we
observed upregulation of MT1-MMP in the transformed cells, the invasive properties can, in
agreement with previous observations (Hotary et al., 2000; 2006; Sabeh et al., 2004), most
likely be ascribed to this protease. Further, collagenases 1 and 3, which are induced by TGF-b
in SCC cells (Leivonen et al., 2006), might also contribute to the invasion of the transformed
A549 cells.
Given the well established and important role of cell surface targeting of proteinases for
cell invasion (Murphy and Gavrilovic, 1999; Hotary et al., 2000; Sabeh et al., 2004), the loss
of pericellular localization of epilysin in the morphologically altered and invasive epilysin
expressing A549 cells also supports a less significant role of epilysin activity in collagen
invasion. Epilysin would thus regulate cell invasion in an indirect fashion through the
induction of other MMPs. Current observations reveal a unique role for epilysin in the
regulation of epithelial cell behavior through the activation of TGF-b, induction of EMT and
acquirement of a type I collagen invasive phenotype.
5.3.2 Implications for epilysin function in vivo
Current results illustrate a dramatic effect for epilysin on the phenotype of epithelial cells.
These results were obtained by overexpressing epilysin in vitro in lung carcinoma cells.
Considering  the  wide  expression  of  epilysin  in  normal,  healthy  tissues  an  effect  of  this
magnitude on epithelial cell morphology is unlikely in vivo. In a physiological setting the
circumstances would be quite different as epilysin expression would be regulated by its
endogenous promoter. This would allow specific interactions with transcriptional regulators
that probably generate much lower expression levels of this enzyme. The cells would also be
surrounded by a physiological ECM which presents growth factors, protease inhibitors and
other proteases that affect the phenotype of the cells and possibly directly modulate epilysin
itself. Further, the A549 cells used in the experimental setup are carcinoma cells which do not
respond to extracellular signals in the same way as normal cells do.
In several experimental setups where epilysin has been overexpressed under different
promoters and selection markers, only cells with low epilysin levels have survived and by
time most cells have lost epilysin expression (Illman S.A., unpublished observations). In the
current  cell  system  we  took  advantage  of  the  pEF-IRES-P  vector  (Materials  and  Methods),
which expresses the inserted cDNA and a puromycin resistance gene as a single mRNA
molecule with an internal ribosomal entry site in between. Using this vector, all selected
puromycin  resistant  cells  are  forced  to  maintain  the  expression  of  epilysin.  In  this  way  we
succeeded in maintaining the epilysin expression at high levels, inducing EMT in the A549
cells (III). In light of these results it is possible that high levels of epilysin are toxic to cells,
and that only a small subset of cells can survive and adapt to the high epilysin contents
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driving them into EMT. This may also explain why the regulation of epilysin expression
varies between cancers of different tissues and different stage of carcinogenesis (section
1.2.3.2).
Nevertheless, these results indicate a possible interaction between epilysin and TGF-b
also under physiological circumstances. In vivo epilysin activity may not induce EMT but,
instead, trigger less permanent changes in TGF-b signaling and cell motility, for example
when it is upregulated in basal skin keratinocytes during wound healing (Lohi et al., 2001;
Saarialho-Kere et al., 2002). Interactions between epilysin and TGF-b may also be of
importance in regulating the functions of the immune system, as indicated by the increased
inflammatory response observed in epilysin deficient mice (section 5.2.3). Epilysin
expression has recently been reported in the developing nervous system in mouse and
Xenopus embryos and also in regenerating nerves in Xenopus, where the neural adhesion
protein NCAM was identified as an in vitro substrate  for  epilysin  (Werner et al., 2007).
Considering the timing of epilysin expression during development and nerve regeneration, the
authors speculate that epilysin could be involved in altering the neural microenvironment
leading to the development of myelin or in inducing a more motile phenotype in the glial
cells. These results support our observation that epilysin can induce the motility of epithelial
cells, and imply that epilysin could modulate the adhesive properties not only of epithelial
cells but also of neural cells through directed proteolysis of cell surface molecules.
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6 Perspective
The generation of genetically targeted mice has provided new insights into the biology of
MMPs. For many MMPs, the relevant in vivo substrates and functions have turned out to be
quite different from what had been expected in view of previous in vitro data. Nevertheless,
studies on these mice have provided proof for the crucial involvement of the MMPs in
development, in the regulation of the immune system and innate immunity, in wound healing
and in pathological processes such as the induction and progression of carcinogenesis and in
arthritis (Egeblad and Werb, 2002; Parks et al., 2004; Martin and Matrisian, 2007; Page-
McCaw et al., 2007).
Future research concerning the individual role for epilysin in the MMP family should be
focused on in vivo experimental systems. Current data elucidate important aspects on the
regulation of epilysin activity through its promoter, activation of the proenzyme and targeted
localization to the cell membrane of epithelial cells. The important finding that epilysin can
induce EMT in epithelial cells in vitro through TGF-b dependent mechanisms, will guide
further research to elucidate the involvement of epilysin in promoting cell motility in TGF-b
regulated processes, such as inflammation and wound healing. The genetically targeted mouse
strain lacking the epilysin gene will be a valuable asset in this pursuit, even though deletion of
genes coding for individual soluble MMPs has not generated severe phenotypes in mouse
models reported so far. In response to various challenges these mice have, however,
frequently displayed individual phenotypes revealing biologically relevant functions and
substrates for the MMPs. It is therefore reasonable to speculate that some of the biologically
relevant functions of epilysin are in the response cascades activated by specific challenges.
One disadvantage with the epilysin null mice is that they have been lacking epilysin
ever since conception, and other MMPs may be upregulated to compensate for the loss of its
enzymatic activity. Challenges inflicted on these mice will therefore reveal only the reactions
of an organism adapted to the lack of epilysin. The generation of mice with a tissue specific
deletion of the epilysin gene could therefore provide additional clues to the function of
epilysin. Conditional inactivation of the epilysin gene in the skin of adult mice could, for
example, reveal a role for epilysin in wound healing without the inflicting compensation by
other  MMPs.  Specific  downregulation  of  epilysin  in  both  time  and  space  could  also  be
achieved through the use of siRNA designed to interfere with epilysin mRNA. Further
knowledge on the biology of epilysin will elucidate if targeted inactivation of this enzyme
could  be  beneficial  in  the  treatment  or  prevention  of  specific  diseases.  On  the  contrary,
enhancement of epilysin function could possibly promote resistance to and recovery from
injury and disease.
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